<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="/ProjectMundo/style/jats-html.xsl"?>
<!DOCTYPE response>
<article article-type="research-article" dtd-version="1.2" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">
    41467
   </journal-id>
   <journal-id journal-id-type="doi">
    10.1038/41467.2041-1723
   </journal-id>
   <journal-title-group>
    <journal-title>
     Nature Communications
    </journal-title>
    <abbrev-journal-title abbrev-type="publisher">
     Nat Commun
    </abbrev-journal-title>
   </journal-title-group>
   <issn pub-type="epub">
    2041-1723
   </issn>
   <publisher>
    <publisher-name>
     Nature Publishing Group UK
    </publisher-name>
    <publisher-loc>
     London
    </publisher-loc>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">
    s41467-024-52388-1
   </article-id>
   <article-id pub-id-type="manuscript">
    52388
   </article-id>
   <article-id pub-id-type="doi">
    10.1038/s41467-024-52388-1
   </article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>
      Article
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/308/575
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/4028/67/1990/283/1897
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/4028/67/1059/2325
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/250/1619/382
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /42/109
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /38/5
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /64/60
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /13/44
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /13/31
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /14
     </subject>
    </subj-group>
    <subj-group subj-group-type="NatureArticleTypeID">
     <subject>
      article
     </subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">
     CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells
    </article-title>
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" equal-contrib="yes" id="Au1">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0009-0009-2392-6416
     </contrib-id>
     <name name-style="western">
      <surname>
       Bexte
      </surname>
      <given-names>
       Tobias
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="author-notes" rid="fn1"/>
    </contrib>
    <contrib contrib-type="author" equal-contrib="yes" id="Au2">
     <name name-style="western">
      <surname>
       Albinger
      </surname>
      <given-names>
       Nawid
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="author-notes" rid="fn1"/>
    </contrib>
    <contrib contrib-type="author" id="Au3">
     <name name-style="western">
      <surname>
       Al Ajami
      </surname>
      <given-names>
       Ahmad
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="aff" rid="Aff6">
      6
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au4">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-5844-1587
     </contrib-id>
     <name name-style="western">
      <surname>
       Wendel
      </surname>
      <given-names>
       Philipp
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
     <xref ref-type="aff" rid="Aff9">
      9
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au5">
     <name name-style="western">
      <surname>
       Buchinger
      </surname>
      <given-names>
       Leon
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au6">
     <name name-style="western">
      <surname>
       Gessner
      </surname>
      <given-names>
       Alec
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff10">
      10
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au7">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-4284-2006
     </contrib-id>
     <name name-style="western">
      <surname>
       Alzubi
      </surname>
      <given-names>
       Jamal
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff11">
      11
     </xref>
     <xref ref-type="aff" rid="Aff12">
      12
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au8">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-9565-2850
     </contrib-id>
     <name name-style="western">
      <surname>
       Särchen
      </surname>
      <given-names>
       Vinzenz
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff13">
      13
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au9">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-2650-586X
     </contrib-id>
     <name name-style="western">
      <surname>
       Vogler
      </surname>
      <given-names>
       Meike
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff13">
      13
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au10">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-1010-296X
     </contrib-id>
     <name name-style="western">
      <surname>
       Rasheed
      </surname>
      <given-names>
       Hadeer Mohamed
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff14">
      14
     </xref>
     <xref ref-type="aff" rid="Aff15">
      15
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au11">
     <name name-style="western">
      <surname>
       Jung
      </surname>
      <given-names>
       Beate Anahita
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff14">
      14
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au12">
     <name name-style="western">
      <surname>
       Wolf
      </surname>
      <given-names>
       Sebastian
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
     <xref ref-type="aff" rid="Aff10">
      10
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au13">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-0865-9582
     </contrib-id>
     <name name-style="western">
      <surname>
       Bhayadia
      </surname>
      <given-names>
       Raj
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au14">
     <name name-style="western">
      <surname>
       Oellerich
      </surname>
      <given-names>
       Thomas
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
     <xref ref-type="aff" rid="Aff10">
      10
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au15">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-1070-0727
     </contrib-id>
     <name name-style="western">
      <surname>
       Klusmann
      </surname>
      <given-names>
       Jan-Henning
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au16">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-4876-802X
     </contrib-id>
     <name name-style="western">
      <surname>
       Penack
      </surname>
      <given-names>
       Olaf
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff14">
      14
     </xref>
     <xref ref-type="aff" rid="Aff16">
      16
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au17">
     <name name-style="western">
      <surname>
       Möker
      </surname>
      <given-names>
       Nina
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff17">
      17
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au18">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-7757-4630
     </contrib-id>
     <name name-style="western">
      <surname>
       Cathomen
      </surname>
      <given-names>
       Toni
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff11">
      11
     </xref>
     <xref ref-type="aff" rid="Aff12">
      12
     </xref>
     <xref ref-type="aff" rid="Aff18">
      18
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au19">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-4158-5872
     </contrib-id>
     <name name-style="western">
      <surname>
       Rieger
      </surname>
      <given-names>
       Michael A.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff10">
      10
     </xref>
     <xref ref-type="aff" rid="Aff19">
      19
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au20">
     <name name-style="western">
      <surname>
       Imkeller
      </surname>
      <given-names>
       Katharina
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="aff" rid="Aff6">
      6
     </xref>
    </contrib>
    <contrib contrib-type="author" corresp="yes" id="Au21">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-8530-1192
     </contrib-id>
     <name name-style="western">
      <surname>
       Ullrich
      </surname>
      <given-names>
       Evelyn
      </given-names>
     </name>
     <address>
      <email>
       evelyn@ullrichlab.de
      </email>
     </address>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
     <xref ref-type="corresp" rid="IDs41467024523881_cor21">
      x
     </xref>
    </contrib>
    <aff id="Aff1">
     <label>
      1
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cvxnb49
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7839.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 9721
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt, Department of Pediatrics
      </institution>
      <institution content-type="org-name">
       Experimental Immunology and Cell Therapy
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff2">
     <label>
      2
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cvxnb49
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7839.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 9721
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt
      </institution>
      <institution content-type="org-name">
       Department of Pediatrics
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff3">
     <label>
      3
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.511198.5
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt
      </institution>
      <institution content-type="org-name">
       Frankfurt Cancer Institute
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff4">
     <label>
      4
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/02y3dtg29
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.433743.4
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 1093 4868
      </institution-id>
      <institution content-type="org-division">
       German Red Cross Blood Service Baden-Württemberg – Hessen
      </institution>
      <institution content-type="org-name">
       Institute for Transfusion Medicine and Immunohematology
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff5">
     <label>
      5
     </label>
     <institution-wrap>
      <institution content-type="org-name">
       University Cancer Center (UCT)
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff6">
     <label>
      6
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cvxnb49
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7839.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 9721
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt, University Hospital
      </institution>
      <institution content-type="org-name">
       Neurological Institute / Edinger Institute
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff7">
     <label>
      7
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/05n911h24
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.6546.1
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 0940 1669
      </institution-id>
      <institution content-type="org-division">
       Institute for Organic Chemistry and Biochemistry
      </institution>
      <institution content-type="org-name">
       Technical University of Darmstadt
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Darmstadt
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff8">
     <label>
      8
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.7497.d
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0492 0584
      </institution-id>
      <institution content-type="org-name">
       German Cancer Consortium (DKTK) partner site Frankfurt/Mainz
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff9">
     <label>
      9
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cdgtt98
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7497.d
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0492 0584
      </institution-id>
      <institution content-type="org-name">
       German Cancer Research Center (DKFZ)
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Heidelberg
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff10">
     <label>
      10
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cvxnb49
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7839.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 9721
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt, University Hospital
      </institution>
      <institution content-type="org-name">
       Department of Medicine II - Hematology and Oncology
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff11">
     <label>
      11
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/0245cg223
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.5963.9
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0491 7203
      </institution-id>
      <institution content-type="org-division">
       Institute for Transfusion Medicine and Gene Therapy
      </institution>
      <institution content-type="org-name">
       Medical Center – University of Freiburg
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Freiburg
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff12">
     <label>
      12
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/0245cg223
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.5963.9
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0491 7203
      </institution-id>
      <institution content-type="org-division">
       Center for Chronic Immunodeficiency
      </institution>
      <institution content-type="org-name">
       Faculty of Medicine, University of Freiburg
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Freiburg
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff13">
     <label>
      13
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cvxnb49
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7839.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 9721
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt
      </institution>
      <institution content-type="org-name">
       Institute for Experimental Pediatric Hematology and Oncology
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff14">
     <label>
      14
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/001w7jn25
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.6363.0
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 2218 4662
      </institution-id>
      <institution content-type="org-division">
       Charité, University Berlin and Humboldt-University Berlin, Department of Hematology
      </institution>
      <institution content-type="org-name">
       Oncology and Tumor Immunology
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Berlin
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff15">
     <label>
      15
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/00mzz1w90
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7155.6
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 2260 6941
      </institution-id>
      <institution content-type="org-division">
       Clinical Pathology Department, Faculty of Medicine
      </institution>
      <institution content-type="org-name">
       Alexandria University
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Alexandria
     </addr-line>
     <country country="EG">
      Egypt
     </country>
    </aff>
    <aff id="Aff16">
     <label>
      16
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.7497.d
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0492 0584
      </institution-id>
      <institution content-type="org-name">
       German Cancer Consortium (DKTK) partner site Berlin
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Berlin
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff17">
     <label>
      17
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.59409.31
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0552 5033
      </institution-id>
      <institution content-type="org-name">
       Miltenyi Biotec B.V. &amp; Co. KG
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Bergisch Gladbach
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff18">
     <label>
      18
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.7497.d
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0492 0584
      </institution-id>
      <institution content-type="org-name">
       German Cancer Consortium (DKTK) partner site Freiburg
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Freiburg
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff19">
     <label>
      19
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04ckbty56
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.511808.5
      </institution-id>
      <institution content-type="org-name">
       Cardio-Pulmonary-Institute
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
   </contrib-group>
   <author-notes>
    <fn fn-type="equal" id="fn1">
     <p>
      These authors contributed equally: Tobias Bexte, Nawid Albinger.
     </p>
    </fn>
    <corresp id="IDs41467024523881_cor21">
     <label>
      x
     </label>
     <email>
      evelyn@ullrichlab.de
     </email>
    </corresp>
   </author-notes>
   <pub-date date-type="pub" publication-format="electronic">
    <day>
     30
    </day>
    <month>
     9
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <pub-date date-type="collection" publication-format="electronic">
    <month>
     12
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <volume>
    15
   </volume>
   <issue seq="8439">
    1
   </issue>
   <elocation-id>
    8439
   </elocation-id>
   <history>
    <date date-type="registration">
     <day>
      5
     </day>
     <month>
      9
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="received">
     <day>
      17
     </day>
     <month>
      1
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="accepted">
     <day>
      30
     </day>
     <month>
      8
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="online">
     <day>
      30
     </day>
     <month>
      9
     </month>
     <year>
      2024
     </year>
    </date>
   </history>
   <permissions>
    <copyright-statement content-type="compact">
     © The Author(s) 2024
    </copyright-statement>
    <copyright-year>
     2024
    </copyright-year>
    <copyright-holder>
     The Author(s)
    </copyright-holder>
    <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
     <license-p>
      <bold>
       Open Access
      </bold>
      This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
      <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
       http://creativecommons.org/licenses/by/4.0/
      </ext-link>
      .
     </license-p>
    </license>
   </permissions>
   <abstract id="Abs1" xml:lang="en">
    <title>
     Abstract
    </title>
    <p id="Par1">
     Mizizi ya antigeni (CAR)-zilizohifadhiwa natural killer (NK) zinatafsiri uwezo wa kuchoma cancer ya myeloid ya kipimo cha kawaida (AML) katika maelezo ya maisha. Hata hivyo, uchomaji wa tumori uliyotengenezwa na NK mara nyingi unafikia kwa sababu ya utengenezwa wa human leukocyte antigen (HLA)-E na receptor ya kumimikana, NKG2A. Hapa, tumeandaa njia yanayoweza kusimamia uchomaji wa CAR-NK uliyotengenezwa na checkpoint ya usimamizi wa HLA-E-NKG2A. Tumeundaa mara zinazohifadhiwa CD33, zinazotumika kwa AML (CAR33) mara pamoja na kusimamia gene ya NKG2A-encoding
     <italic>
      KLRC1
     </italic>
     kwa kutumia CRISPR/Cas9. Kutumia analizi ya single-cell multi-omics, tumeambatana na sifa za transcription za uaktivishaji na umatibio katika CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK, zinazoyajulikana baada ya ujumbe na nyimbo za AML. Pia, CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK zinatafsiri uwezo wa kuchoma cancer ya AML kwa uwezo mkubwa kwa maelezo ya nyimbo za AML na blast za kwanza katika maelezo ya maisha na katika maelezo ya maisha. Kwa hivyo, tumeiitisha kwamba CAR-NK zinazohifadhiwa NKG2A zina uwezo wa kusimamia usimamizi wa immune katika AML.
    </p>
   </abstract>
   <abstract abstract-type="ShortSummary" id="Abs2" xml:lang="en">
    <p id="Par2">
     NK cell-based therapy can kill acute myeloid leukemia (AML), but immune suppression may occur. Here the authors overcome the immunosuppression of AML-targeted CAR33-NK cells via non-viral CRISPR-editing of the immune checkpoint NKG2A, leading to an enhanced potency of the CAR-NK cell product with sustained anti-tumor efficacy.
    </p>
   </abstract>
   <kwd-group kwd-group-type="hierarchical" vocab="FoR" vocab-identifier="ANZSRC 2008">
    <kwd content-type="term" vocab-term-identifier="11">
     Medical and Health Sciences
    </kwd>
    <nested-kwd>
     <kwd content-type="term" vocab-term-identifier="1107">
      Immunology
     </kwd>
    </nested-kwd>
   </kwd-group>
   <custom-meta-group>
    <custom-meta>
     <meta-name>
      publisher-imprint-name
     </meta-name>
     <meta-value>
      Nature Portfolio
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-issue-count
     </meta-name>
     <meta-value>
      1
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-article-count
     </meta-name>
     <meta-value>
      8439
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-pricelist-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-holder
     </meta-name>
     <meta-value>
      Springer Nature Limited
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-contains-esm
     </meta-name>
     <meta-value>
      Yes
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-month
     </meta-name>
     <meta-value>
      9
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-day
     </meta-name>
     <meta-value>
      5
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-product
     </meta-name>
     <meta-value>
      NonStandardArchiveJournal
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-grants-type
     </meta-name>
     <meta-value>
      OpenChoice
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      metadata-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      abstract-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodypdf-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodyhtml-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bibliography-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      esm-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      online-first
     </meta-name>
     <meta-value>
      false
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-file-reference
     </meta-name>
     <meta-value>
      BodyRef/PDF/41467_2024_Article_52388.pdf
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-type
     </meta-name>
     <meta-value>
      Typeset
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      target-type
     </meta-name>
     <meta-value>
      OnlinePDF
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-type
     </meta-name>
     <meta-value>
      OriginalPaper
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-primary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-collection
     </meta-name>
     <meta-value>
      Science (multidisciplinary)
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      open-access
     </meta-name>
     <meta-value>
      true
     </meta-value>
    </custom-meta>
   </custom-meta-group>
  </article-meta>
 </front>
 <body>
  <sec id="Sec1" sec-type="introduction">
   <title>
    Ujumbe
   </title>
   <p id="Par3">
    Uchunguzi wa teknolojia za CAR-T hadi ya chimeric antigen receptor (CAR) zimeleta kuhakikishwa ya bidhaa nyingi kwa uchaguzi wa matatizo yanayohusiana na zell za B
    <sup>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
     ,
     <xref ref-type="bibr" rid="CR2">
      2
     </xref>
     ,
     <xref ref-type="bibr" rid="CR3">
      3
     </xref>
     ,
     <xref ref-type="bibr" rid="CR4">
      4
     </xref>
     ,
     <xref ref-type="bibr" rid="CR5">
      5
     </xref>
    </sup>
    . Pamoja na bidhaa za CAR-T zinazohakikishwa na U.S. Food and Drug Administration na European Medicines Agency, zell za CAR-natural killer (NK) zinazotumika kwa CD19 zimehakikishwa kuwa salama na kuna ufanisi sawa na CAR-T katika majaribio ya kliniki
    <sup>
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
     ,
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
    </sup>
    . Ufumbuzi wa bidhaa za CAR kwa uchaguzi wa acute myeloid leukemia (AML) ni zaidi ya changamoto kwa sababu ya ukakamavu wa maradhi na ukosefu wa antigens yanayohusiana na AML tu
    <sup>
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
     ,
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
    </sup>
    . Hata hivyo, antigen moja ya kumekuwa na umuhimu kwa CAR-based cell therapy ni CD33, ambayo inatolewa kwenye blast za leukemic na zell za kusababisha leukemia katika up to 88% wa wataalamu wa AML, na matokeo ya majaribio ya preclinical yameonyesha ufanisi wa anti-AML ya CD33-specific CAR-T cells
    <sup>
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
     ,
     <xref ref-type="bibr" rid="CR10">
      10
     </xref>
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
     ,
     <xref ref-type="bibr" rid="CR12">
      12
     </xref>
    </sup>
    . Alternatif moja ya kumekuwa na umuhimu kwa CAR-T cell therapy ni zell za NK zinazotolewa kwa njia ya adoptive, ambazo zina muda mfupi zaidi kuliko zell za T, zinazohusiana na mafadhaiko mengi zaidi, na zinazo haki ya ufanisi wa CAR-independent killing, ambayo imeonyeshwa katika muktadha wa NKG2D-ligand-expressing AML
    <sup>
     <xref ref-type="bibr" rid="CR13">
      13
     </xref>
     ,
     <xref ref-type="bibr" rid="CR14">
      14
     </xref>
     ,
     <xref ref-type="bibr" rid="CR15">
      15
     </xref>
     ,
     <xref ref-type="bibr" rid="CR16">
      16
     </xref>
     ,
     <xref ref-type="bibr" rid="CR17">
      17
     </xref>
     ,
     <xref ref-type="bibr" rid="CR18">
      18
     </xref>
    </sup>
    .
   </p>
   <p id="Par4">
    Katika kazi ya majaribio ya preclinical ya hivi karibuni, tumeundaa zell za NK za CD33-directed CAR (CAR33) zinazotolewa kwenye blast za CD33 AML katika muktadha wa xenograft in vivo
    <sup>
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
     ,
     <xref ref-type="bibr" rid="CR20">
      20
     </xref>
    </sup>
    . Hata hivyo, ufanisi wa CAR33-NK zinaweza kuwa na changamoto kwa sababu ya upungufu wa immune checkpoints katika muktadha wa tumor ya immunosuppressive. Kwa ujumla, ufanisi wa zell za NK inahakikishwa kwa mizani ya matokeo za kujihusisha na matokeo za kusababisha na kusababisha zinazotolewa kwenye kifupi cha zell. Kati ya hayo, matokeo moja muhimu ya kusababisha ni NK group 2A (NKG2A) ambayo inatolewa na gene ya
    <italic>
     KLRC1
    </italic>
    . Inatambulisha protein ya MHC I ya non-classical HLA-E, ambayo inatolewa sana kwenye zell za kibaya
    <sup>
     <xref ref-type="bibr" rid="CR21">
      21
     </xref>
     ,
     <xref ref-type="bibr" rid="CR22">
      22
     </xref>
     ,
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
     ,
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     ,
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    . Sisi na wengine tumeonyesha kuwa kusababisha matokeo ya NKG2A-HLA-E kwa kutumia antibodies za NKG2A-blocking, kama vile monalizumab au CRISPR/Cas9-based disruption ya
    <italic>
     KLRC1
    </italic>
    katika zell za NK, inaweza kuboresha sana ufanisi wa cytotoxicity ya zell za NK kwa multiple myeloma
    <sup>
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
     ,
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     ,
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    . Tumeonyesha pia kuwa muktadha mbalimbali ya AML, na pia blast za AML za kwanza, zinatolewa mada mengi ya HLA-E, na kuwa HLA-E inatolewa sana baada ya kujihusisha na IFN-γ, cytokine ambayo inajulikana kuwa inatolewa sana na CAR-NK cells baada ya kujihusisha na zell za target. Kwa hiyo, tumeamini kuwa matokeo ya NKG2A-HLA-E inaweza kuwa na umuhimu mkubwa katika CAR-NK cell exhaustion na kuwa kusababisha gene ya NKG2A-coding
    <italic>
     KLRC1
    </italic>
    katika CAR-NK za CD33 zingezidi kuboresha ufanisi wao wa anti-AML killing
    <sup>
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    .
   </p>
   <p id="Par5">
    Katika kazi hii, tumeonyesha ufumbuzi wa zell za NK za dual-modified kwa kujumlisha CAR33 transduction ya lentiviral na CRISPR/Cas9-mediated disruption ya gene ya
    <italic>
     KLRC1
    </italic>
    . Zell za CAR33-
    <italic>
     KLRC1
    </italic>
    -NK zinazopunguza zimeonyesha ufanisi wa cytotoxicity zaidi sana kuliko CAR33-NK au
    <italic>
     KLRC1
    </italic>
    -NK cells kwa muktadha ya CD33/HLA-E cell line OCI-AML2 na cohort ya blast za kwanza za wataalamu
    <sup/>
    .
   </p>
   <p id="Par6">
    Maelezo ya single-cell transcriptome na epitope yameonyesha matokeo za gene expression zinazohusiana na ufanisi, umadhi, na cytotoxicity katika CAR33-NK na CAR33-
    <italic>
     KLRC1
    </italic>
    -NK zinazopunguza, kulingana na ufanisi wa kuboresha ufanisi. Kwa ujumla, CAR33-
    <italic>
     KLRC1
    </italic>
    -NK cells zimeonyesha upungufu wa IFN-γ zaidi kuliko
    <italic>
     KLRC1
    </italic>
    -NK na CAR33-NK cells, ambazo ziliendelea baada ya kujihusisha na zell za target
    <sup/>
    .
   </p>
   <p id="Par7"/>
  </sec>
  <sec id="Sec2" sec-type="results">
   <title>
    Matokeo
   </title>
   <sec id="Sec3">
    <title>
     Dual genetically engineered CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK cells combine CAR insertion with reduced NKG2A expression
    </title>
    <p id="Par8">
     CAR33-NK zimeundwa kwa usimamizi wa lentivirus ya NK zaidi za kwanza zilizotolewa kutoka kwenye damu ya mizizi (PB) ya wateja wa afya (Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S1a
     </xref>
     ) ili kutoa CAR ya jina ya pili yanayohisi CD33 kama imeshowingwa katika Fig.
     <xref ref-type="fig" rid="Fig1">
      1a
     </xref>
     <sup>
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
     </sup>
     . Baada ya usimamizi wa usimamizi, tofauti ya CAR ilipatikana katika 30-70% ya nyimbo za NK (Fig.
     <xref ref-type="fig" rid="Fig1">
      1b, c
     </xref>
     ). Kwa ajili ya NKG2A-knockout, nyimbo za NK zinazohisi (NT)-NK na CAR33-NK ziliundwa kwa CRISPR/Cas9 ribonucleoprotein (RNP) complex yanayohisi locus ya
     <italic>
      KLRC1
     </italic>
     . Usimamizi wa RNP si ya virus ilipanda kwa njia kubwa tofauti ya nyimbo za NKG2A-athibiti kwa kira ~50% kulingana na nyimbo za NT-NK (~90% NKG2A) (Fig.
     <xref ref-type="fig" rid="Fig1">
      1b, d
     </xref>
     ). Tofauti ya gene ya
     <italic>
      KLRC1
     </italic>
     ya kipimo kubwa ilipatikana kwa nyimbo za NK zilizotathminiwa kwa kusimamiza au kusimamiza CAR, kwa kusimamizi kwa T7 endonuclease 1 (T7E1; &gt;67%) na kwa kipimo cha insertion/deletion (indels) kwa Inference of CRISPR Edits (ICE; &gt;90%) analyses (Fig.
     <xref ref-type="fig" rid="Fig1">
      1e, f
     </xref>
     ; Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S1b
     </xref>
     <sup/>
     . Uhusiano wa
     <italic>
      KLRC1
     </italic>
     -targeting CRISPR/Cas9 nuclease katika nyimbo za NK imeonyeshwa mara kwa mara
     <sup>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
     </sup>
     . Tofauti ya indel analysis ilipatikana +1 insertion ya kipimo kubwa iliokufuata −15 deletion mara kwa mara katika mitandao mitatu mbalimbali katika kusimamiza au kusimamiza CAR. −15 deletion inaweza kujulikana kwa kipimo cha micro-homology sequences zinazofikia kwenye tofauti ya cleavage site (Fig.
     <xref ref-type="fig" rid="Fig1">
      1f
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S1c
     </xref>
     ,
     <xref ref-type="supplementary-material" rid="MOESM1">
      1d
     </xref>
     ). Ufugaji ulipanda sawa katika sifa zote nne kulingana na muda (NT-NK cells,
     <italic>
      KLRC1
     </italic>
     -NK cells, CAR33-NK cells na CAR33-CAR-
     <italic>
      KLRC1
     </italic>
     -NK cells; iliyotunjazwa kwa log-fold expansion rate, Fig.
     <xref ref-type="fig" rid="Fig1">
      1g
     </xref>
     ). Hata hivyo, tulipata tofauti ya muda wa tofauti ya nyimbo za kasi kufuata usimamizi wa electric pulse kwa kusimamiza gene knockout ya RNP (Fig.
     <xref ref-type="fig" rid="Fig1">
      1g
     </xref>
     ). Tofauti ya nyimbo za kasi ilikuwa mara kwa mara kulingana na usimamizi wa nucleofection kwa siku 9 (tarehe ya CRISPR/Cas9
     <italic>
      KLRC1
     </italic>
     -KO generation), lakini sifa zote za uchakata zilipata tofauti sawa za kipimo kwa kisa kulingana na siku 13 (Fig.
     <xref ref-type="fig" rid="Fig1">
      1g
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S2a–c
     </xref>
     ). Usimamizi wa nucleofection na sgRNAs zinazohisi au MOCK nucleofection ya kawaida ilipata tofauti sawa ya kipimo cha NK kulingana na sgRNA yanayohisi
     <italic>
      KLRC1
     </italic>
     katika sifa zote za CAR33-NK cell na NT-NK cell (Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S2b, c
     </xref>
     ). Kwa muhimu, usimamizi wa CRISPR/Cas9 ya
     <italic>
      KLRC1
     </italic>
     katika CAR33-NK cells ilipatikana tofauti ya gene ya kipimo kubwa iliyotoa tofauti kubwa ya tofauti ya NKG2A ya kipimo ya kasi (Fig.
     <xref ref-type="fig" rid="Fig1">
      1b
     </xref>
     )
     <sup/>
     .
     <fig id="Fig1" position="float">
      <label>
       Fig. 1
      </label>
      <caption xml:lang="en">
       <title>
        Ujenzi wa CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK zinazoweza kusimamia na uchanganuzi wa CRISPR/Cas9.
       </title>
       <p>
        <bold>
         a
        </bold>
        Shughuli za kwenye mtaa ya ujenzi wa CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK zinazoweza kusimamia.
        <bold>
         b
        </bold>
        Mifano ya mawasilisho ya flow cytometry ya CAR33 na NKG2A kwenye zinazoweza kusimamia NK.
        <bold>
         c
        </bold>
        Uchanganuzi wa flow cytometry wa CAR33 kwenye kifupi kwa muda (
        <italic>
         n
        </italic>
        = 6–9). Mean ± SD. CAR33 vs CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        : d14 (
        <italic>
         n
        </italic>
        = 0.1158), d21 (
        <italic>
         n
        </italic>
        = 0.1296), d28 (
        <italic>
         n
        </italic>
        = 0.8095).
        <bold>
         d
        </bold>
        Uchanganuzi wa flow cytometry wa NKG2A baada ya CRISPR/Cas9 knockout ya geni
        <italic>
         KLRC1
        </italic>
        (
        <italic>
         n
        </italic>
        = 7). Mean ± SD.
        <bold>
         e
        </bold>
        Urefu wa
        <italic>
         KLRC1
        </italic>
        ya kusimamia kwenye kifupi iliyotolewa kwa Inference of CRISPR Edits (ICE) na T7E1 assay kwa CAR-transduced (+CAR) na NK zinazoweza kusimamia (−CAR) (
        <italic>
         n
        </italic>
        = 3). Mean ± SD.
        <bold>
         f
        </bold>
        Mawasilisho ya Insertion/deletion (indel) yaliyotolewa kwa ICE analysis kutoka kwa wateja wawili na wachezo (D1, D2, D3).
        <bold>
         g
        </bold>
        Expansion-fold na workflow ya ujenzi wa non-transduced (NT)-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK cells kwenye kifupi kwa IL-2 (500 U/mL) na IL-15 (10 ng/ml Miltenyi Biotec au 50 ng/mL CellGenix) (
        <italic>
         n
        </italic>
        = 7). Mean ± SD (ns = 0.9991). Uchanganuzi wa tathmini ulitolewa kwa two-way ANOVA (
        <bold>
         c
        </bold>
        ,
        <bold>
         g
        </bold>
        ) na paired Student’s
        <italic>
         t
        </italic>
        test (
        <bold>
         d
        </bold>
        ,
        <bold>
         e
        </bold>
        ). Kifupi cha
        <italic>
         n
        </italic>
        ni biological replicates (kutoka kwa wateja wasafi) (
        <bold>
         c
        </bold>
        –
        <bold>
         e
        </bold>
        ,
        <bold>
         g
        </bold>
        ).
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig1_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec4">
    <title>
     Multi-omics analysis reveals activated cell state of CAR33-(
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     )-NK cells
    </title>
    <p id="Par9"/>
    <p id="Par10">
     <fig id="Fig3" position="float">
      <label>
       Fig. 3
      </label>
      <caption xml:lang="en">
       <title>
        CAR33- na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK cell pools yanapewa sehemu ya zaidi ya nyimbo za NK nyimbo zinazotumika.
       </title>
       <p>
        <bold>
         a
        </bold>
        t-SNE representation ya NK cells kwa kipengele cha kikoa kulingana na RNA yao na wasafi wa protein. Nyimbo zinazotumika zinazoweza kuchanganyika kulingana na masharti tofauti (NT-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK cells).
        <bold>
         b
        </bold>
        Analysis ya kipengele cha kwanza ya nyimbo zinazotumika kulingana na CITE-seq ya wachezaji wawili tofauti.
        <bold>
         c
        </bold>
        Pooled subclustering ya wasafi ya nyimbo zinazotumika kutoka kwa masharti zote (t-SNE representation kama inavyoonekana katika (
        <bold>
         a
        </bold>
        )). Louvain clustering kulingana na PCA results.
        <bold>
         d
        </bold>
        Uwezo wa nyimbo zinazotumika kulingana na sehemu ya nyimbo zote zinazochanganyika.
        <bold>
         e
        </bold>
        Uwezo wa nyimbo zinazotumika kulingana na sehemu ya nyimbo zote zinazochanganyika kama sehemu ya pools ya NK cells. Kwa kila pool ya NK cells (NT-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK), uwezo wa nyimbo zote zinazochanganyika zinachukua moja.
        <bold>
         f
        </bold>
        Skora ya wasafi ya gene au protein zinazochaguliwa kulingana na cluster. Gene na protein zinazochaguliwa zinazoweza kuchanganyika kulingana na kazi (Checkpoint &amp; Suppressive Regulators, Downstream TCR signaling, Lymphocyte Activation, Mature NK Cells). Kila dot inawakilisha gene au protein moja. Skora ya wasafi ya feature X kulingana na cluster Y ni moyo wa wasafi wa feature X kwa nyimbo zote zinazotumika kwenye cluster Y iliyogawanyika kwa moyo wake kwa nyimbo zote zinazotumika kwenye clusters zote (zilizohusishika cluster Y, iliyotumika kama log10). Skora juu ya sifuri inamaanisha upatikanaji wa wasafi fulani kwenye cluster fulani kulingana na clusters zingine. Mauadili machungu machora median skora ya wasafi zao (statistics ni medians kwa gene).
        <bold>
         g
        </bold>
        Kuchaguliwa kwa gene na protein kulingana na kazi zao. Maelezo ya kila kundi na wasafi zao zinazochaguliwa zinazoweza kuzungumzwa.
        <bold>
         a
        </bold>
        ,
        <bold>
         c
        </bold>
        –
        <bold>
         f
        </bold>
        Analysis ya kawaida ya nyimbo zinazotumika kutoka kwa wachezaji D1.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig3_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec5">
    <title>
     Knockout of immune checkpoint NKG2A boosts anti-AML activity of CAR33-NK cells in vitro
    </title>
    <p id="Par11">
     <fig id="Fig4" position="float">
      <label>
       Fig. 4
      </label>
      <caption xml:lang="en">
       <title>
        KO ya receptor ya kumimikana NKG2A (
        <italic>
         KLRC1
        </italic>
        ) kumaliza uwezo wa CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK cells kwa AML in vitro.
       </title>
       <p>
        <bold>
         a
        </bold>
        Uchambuzi wa muda mfupi (4 saa) na muda mrefu (24 saa) kulingana na flow cytometry ya NK cells kwa CD33
        <sup>
         +
        </sup>
        /HLA-E
        <sup>
         +
        </sup>
        OCI-AML2 cells kwa E:T ratios zinazochaguliwa (
        <italic>
         n
        </italic>
        = 5). Mean ± SD.
        <bold>
         b
        </bold>
        Uchambuzi wa CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK kwa kutumia IncuCyte-S3 imager. CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK cells zilizochanganyika kwa GFP
        <sup>
         +
        </sup>
        OCI-AML2 cells kwa 26.5 saa na upatikanaji wa fluorescence ulikuwa unachukua muda (OCI-AML2 only condition
        <italic>
         n
        </italic>
        = 3; rest
        <italic>
         n
        </italic>
        = 4). Median + range.
        <bold>
         c
        </bold>
        Sura zinazochaguliwa zilizotolewa baada ya 24.5 saa ya IncuCyte analysis ya NT-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK cells zilizochanganyika kwa GFP
        <sup>
         +
        </sup>
        OCI-AML2 cells (E:T = 0.5:1). Nyimbo zinazotumika zinazoweza kuchanganyika kulingana na wasafi wa GFP yao. Nyimbo zinazokufa zinazochanganyika kwa rangi nyekundu kwa wasafi wa Annexin V. Kwa kuchambuzi, platform ya IncuCyteS3 iliyotumika.
        <bold>
         d
        </bold>
        Caspase-cleavage kwa OCI-AML2 cells zinazotumika baada ya 2 saa ya co-culture na NK cells iliyotumika kwa western blot (one representative experiment of 3 iliyotumika; “clvd” = “cleaved”, “ctrl” = “control”).
        <bold>
         e
        </bold>
        qPCR gene expression analysis ya NT-,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -, CAR33- na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK cells baada ya 2 saa ya co-culture na OCI-AML2 cells (E:T = 3:1) (
        <italic>
         n
        </italic>
        = 5). Mean ya technical triplicates ± SD. Uchambuzi wa statistical iliyotumika kwa two-way ANOVA (
        <bold>
         a
        </bold>
        ), paired Student’s
        <italic>
         t
        </italic>
        test (
        <bold>
         b
        </bold>
        ), paired Wilcoxon (
        <bold>
         e
        </bold>
        ). Entity ya
        <italic>
         n
        </italic>
        ni biological replicates (kutoka kwa wachezaji wawili tofauti) (
        <bold>
         a
        </bold>
        ,
        <bold>
         b
        </bold>
        ,
        <bold>
         e
        </bold>
        ).
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig4_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec6">
    <title>
     HLA-E is a homogenously expressed target in AML patients and CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK cells demonstrated superior killing capacity against patient-derived blasts cells ex vivo
    </title>
    <p id="Par12"/>
    <p id="Par13">
     CAR33-
     <italic>
      KLRC1
     </italic>
     -NK zinazowezaa kufanya kazi bora kwa saba za maoni yote na wachezaji wote mara kwa mara kuliko NT-,
     <italic>
      KLRC1
     </italic>
     - au CAR33-NK zinazowezaa kufanya kazi kwa blast za AML kutoka kwa wachezaji wote (Fig.
     <xref ref-type="fig" rid="Fig5">
      5f, g
     </xref>
     , jumla
     <italic>
      n
     </italic>
     = 10). Hii ni kweli pia kwa blast zinazotokana na wachezaji wenye subseti za molecular ya hatari ya juu (Fig.
     <xref ref-type="fig" rid="Fig5">
      5g
     </xref>
     , Supplementary Table
     <xref ref-type="supplementary-material" rid="MOESM1">
      1
     </xref>
     ,
     <italic>
      n
     </italic>
     = 6)
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec7">
    <title>
     CITE-seq analysis of CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK cells revealed preserved activation state and reduced cell cycle activity following AML contact
    </title>
    <p id="Par14">
     Matokeo yetu ya awali yanayonyesha kuwa kujitokeza na CAR33 pamoja na kusambaza gene ya receptor ya kurejelea NKG2A kwa njia ya synergistic inaweza kuboresha uwezo wa kufanya kazi wa NK cells bila kusababisha mabadiliko makubwa ya transcriptional au expression ya marker za surface katika pool za nyuzi zinazohusiana. Kusoma kwa kujua kama uwezo bora wa kufanya kazi ya CAR33-
     <italic>
      KLRC1
     </italic>
     -NK zinaweza kuchanganyika na mabadiliko ya phenotype ya pool za NK cells baada ya kujikuta na AML cells, tuliendelea kufanya CITE-seq analysis ya nyuzi zinazohusiana na zinazofanya kazi (data ya cytotoxicity yaliyotolewa katika Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S4d
     </xref>
     ) baada ya co-culture ya 2 saa na OCI-AML2 cells (E:T = 1:1). Nyuzi zinazohusiana na AML zinazohusiana na GFP ziliweka kwenye flow cytometer-based cell sorting. Kama ilivyotolewa kwa CITE-seq analyses kabla ya co-culture, NT-NK cells ziliweka kama GFP,
     <italic>
      KLRC1
     </italic>
     -NK cells ziliweka kama GFP/NKG2A, CAR33-NK ziliweka kama GFP/CAR- na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK cells ziliweka kama GFP/NKG2A/CAR cells (Fig.
     <xref ref-type="fig" rid="Fig6">
      6a
     </xref>
     ). Wakati data ya expression ya NK cells baada ya co-culture iliyotengenezwa na data ya kabla ya co-culture, tuliamua mufano wa mabadiliko wa gene na surface marker expression iliyotengenezwa katika saba za nyuzi zote (Fig.
     <xref ref-type="fig" rid="Fig6">
      6b, c
     </xref>
     ). Uwezo bora wa kujitokeza baada ya kujikuta na cells za leukemic iliyotengenezwa kwa cytokines na chemokines, kama vile
     <italic>
      CSF2, CCL3
     </italic>
     ,
     <italic>
      CCL4
     </italic>
     , na TNF, kwa regulators za immune responses, kama vile
     <italic>
      IL3, IL1RN
     </italic>
     , CD69, na CD81, na pia kwa regulators za transcriptional, kama vile
     <italic>
      MYC
     </italic>
     <bold>
      (
     </bold>
     Fig.
     <xref ref-type="fig" rid="Fig6">
      6b
     </xref>
     ). Levels ya expression ya
     <italic>
      FCGR3A
     </italic>
     /CD16 na
     <italic>
      TNFSF8
     </italic>
     ziliendelea kujitoa baada ya kujikuta na AML katika saba za nyuzi zote (Fig.
     <xref ref-type="fig" rid="Fig6">
      6b, c
     </xref>
     ). Mabadiliko hayo ya expression iliyotengenezwa na kujikuta na AML iliyokuwa na nguvu zaidi katika CAR33 na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK cells kuliko NT na
     <italic>
      KLRC1
     </italic>
     -NK cells, ambayo ni sawa na uwezo bora wa kufanya kazi wa saba za nyuzi hizi (Fig.
     <xref ref-type="fig" rid="Fig6">
      6c
     </xref>
     ). CAR33- na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK cells hawakubali alama za kujitoka kwa njia ya upregulation ya molecules za kurejelea au checkpoint kama vile
     <italic>
      HAVRC2
     </italic>
     (TIM3),
     <italic>
      TIGIT
     </italic>
     ,
     <italic>
      CD96
     </italic>
     ,
     <italic>
      PD-
     </italic>
     1 au
     <italic>
      CTLA-4
     </italic>
     kulingana na qPCR analysis baada ya 2 saa ya co-culture na OCI-AML2 cells (Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S6a
     </xref>
     )
     <sup/>
     .
    </p>
    <p id="Par15">
     Tuliamua kuzingatia uhusiano wa single-cell wa pool za nyuzi zote baada ya kujikuta na AML cells kusoma kwa kujua mabadiliko yanayotengenezwa na activation ya NK cells. Kama tulivyozingatia pool za nyuzi kabla ya kujikuta, composition ya
     <italic>
      KLRC1
     </italic>
     -NK pool ilikuwa na usimamizi wa NT-NK pool na composition ya CAR33-NK pool ilikuwa na usimamizi ya CAR33-
     <italic>
      KLRC1
     </italic>
     -NK cell pool (Fig.
     <xref ref-type="fig" rid="Fig6">
      6d
     </xref>
     ). Wakati samples za cells ziliweka kwenye clusters kulingana na profiles za gene na surface marker expression, tuliamua kwamba clusters za transcriptional zinazokuwa na levels ya genes zinazotengenezwa na co-culture, kama vile
     <italic>
      CCL4, CCL3, IFNG, TNF
     </italic>
     , na
     <italic>
      MYC
     </italic>
     (Fig.
     <xref ref-type="fig" rid="Fig6">
      6d–f
     </xref>
     , cluster 1 na 4), ziliendelea katika CAR33-NK na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK cells kuliko pool za nyuzi zingine. Uwezo bora wa cells zinazowezaa kutoa IFN-γ (cluster 1 ya transcriptional), na kwa hivyo levels ya IFN-γ zinazokuwa kwenye supernatants ya 4 saa ya co-cultures ziliendelea katika CAR33-
     <italic>
      KLRC1
     </italic>
     -NK cells baada ya co-culture (Fig.
     <xref ref-type="fig" rid="Fig6">
      6e–i
     </xref>
     ) kuliko CAR33-NK cells, ambayo ni sawa na kujifunza kwamba pool hii iliyowezaa kufanya kazi bora
     <sup/>
     .
    </p>
    <p id="Par16"/>
   </sec>
   <sec id="Sec8">
    <title>
     Low numbers of CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK cells can eliminate leukemia-initiating cells located in the bone marrow
    </title>
    <p id="Par17"/>
   </sec>
  </sec>
  <sec id="Sec9" sec-type="discussion">
   <title>
    Mazungumzo
   </title>
   <p id="Par18">
    Ufanisi wa kutumia CAR-NK za kwanza ni njia ya maambukizi ya kusafi na kuhitaji kwa ajili ya mafanikio. Katika majaribio ya mada I/II, CAR-NK za CD19 zilizotolewa kutoka kwa watu wengine zilipata mafanikio wazuri wa mazoezi kwa watafsiri wenye uhalifu wa B-cells, pamoja na usafi bora wa kusafi ambako hakuna matukio ya CRS (cytokine release syndrome) kamili, neurotoxicity, au graft-versus-host disease (GvHD)
    <sup>
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
     ,
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
     ,
     <xref ref-type="bibr" rid="CR35">
      35
     </xref>
    </sup>
    . Kutumia NK cells kwa uundaji wa CAR effector cells ina faida za kujitambua, hasa kwa ajili ya antigens zinazohusiana na hatari ambazo hawana kurekebuka kwa nyumba ya hatari tu, kama vile AML
    <sup>
     <xref ref-type="bibr" rid="CR36">
      36
     </xref>
    </sup>
    . Katika majaribio ya kuanza, maambukizi ya AML kwa NK cells zisizotolewa zilipatikana kuwa salama, na kuna mazoezi ya blast zinazozungumzwa kwa watafsiri wengi
    <sup>
     <xref ref-type="bibr" rid="CR37">
      37
     </xref>
    </sup>
    . Hasa, matumizi ya NK cells zinazohusiana na cytokines zinapokuwa na uwezo wa kusafisha AML, na umuhimu mkubwa wa IL-15 au IL-12/15/18 zinazohusiana na cytokines zinazokujenga memory ya NK cells
    <sup>
     <xref ref-type="bibr" rid="CR16">
      16
     </xref>
    </sup>
    . Hata hivyo, mazingira ya kusafisha ya nyumba ya hatari ya AML na upigvijisho wa hatari zinaweza kuhisi ufanisi wa maambukizi ya hatari. Analizesho za single-cell zimejulikana, ambazo zimeonyesha njia za uundaji wa NK cells kwenye nyumba ya hatari na alama ya kusafisha zinazohusiana na AML, ambazo zimekuwa na athari kubwa kwa ufanisi wa NK cells
    <sup>
     <xref ref-type="bibr" rid="CR38">
      38
     </xref>
     ,
     <xref ref-type="bibr" rid="CR39">
      39
     </xref>
    </sup>
    . Kwa muhimu, uwezo wa kusafisha wa hatari wa NK cells ina uwezo wa kusafisha pia hatari zinazotokana na kushuka kwa CAR-target antigen expression, ambayo bado haitawezeki katika CAR-T cell therapies
    <sup>
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
    </sup>
    . Pia, mada ya INF-γ zinazokujenga zinaweza kuhisi ufanisi wa kusafisha wa NK cells kwa muda wa kusafisha hatari
    <sup>
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     ,
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    . Mada ya INF-γ zinazokujenga zinazojulikana pia kwa CAR-NK cells zinazohusiana na CD33 baada ya kusafisha hatari katika AML, ambazo zinaweza kusababisha upigvijisho wa molecules za kusafisha kama vile protein ya MHC I ya kawaida HLA-E
    <sup>
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
     ,
     <xref ref-type="bibr" rid="CR20">
      20
     </xref>
     ,
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     ,
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    . Kwa hivyo, ufanisi wa kusafisha AML inaweza kuhisi kwa njia ya receptors za checkpoint za kusafisha za kusafisha kama vile NKG2A, ambazo zinatokana na HLA-E, ambayo zinaweza kujulikana kwa hatari zinazohusiana na hatari
    <sup>
     <xref ref-type="bibr" rid="CR21">
      21
     </xref>
     ,
     <xref ref-type="bibr" rid="CR22">
      22
     </xref>
     ,
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
    </sup>
    . Data zilizopatikana kwa kundi letu na wengine zilipatikana kuwa HLA-E/NKG2A inhibition inaweza kujitambuliwa kwa njia ya blocking au CRISPR/Cas9 NKG2A modification
    <sup>
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
     ,
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     ,
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    . Katika kazi hii, tumeandaa njia ya kujenga NK cells zinazotolewa kwa CAR33 na CRISPR/Cas9-mediated
    <italic>
     KLRC1
    </italic>
    gene disruption. CAR33-
    <italic>
     KLRC1
    </italic>
    -NK cells zilizopatikana zilipata ufanisi wa kusafisha wa kubora kwa CD33/HLA-E target cells kulingana na CAR33-NK cells au
    <italic>
     KLRC1
    </italic>
    -NK cells kwa AML cell lines, blast cells za AML zinazotolewa kutoka kwa watafsiri, na katika model ya murine xenograft AML in vivo
    <sup/>
    .
   </p>
   <p id="Par19"/>
   <p id="Par20"/>
   <p id="Par21"/>
   <p id="Par22"/>
   <p id="Par23">
    Kwa ufumbuzi, wakati kuchanganya mazoezi ya CAR33-
    <italic>
     KLRC1
    </italic>
    -NK kwenye mazoezi ya 4 saa na 24 saa ya kusimamia uchafu kwa nyuzi OCI-AML2, zana CAR33-NK zilikuwa na uwezo mkubwa wa kusimamia uchafu kwa muda mfupi linavyopigwa na uongezi wa chaguo la caspase-3 na kusimamia perforin na granzyme, wakati
    <italic>
     KLRC1
    </italic>
    -NK zilizipatia uwezo wao wa kusimamia uchafu kwa muda mrefu (Fig.
    <xref ref-type="fig" rid="Fig4">
     4
    </xref>
    ). Kwa muhimu, CAR33-
    <italic>
     KLRC1
    </italic>
    -NK zinapata faida kwa mabadiliko yoyote, hasa kwa nisaba zinazohusu E:T, ambayo yanayonyesha hali za physiologic zinazopunguza kwenye binadamu (Figs.
    <xref ref-type="fig" rid="Fig5">
     5
    </xref>
    ,
    <xref ref-type="fig" rid="Fig7">
     7
    </xref>
    )
    <sup>
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
     ,
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
     ,
     <xref ref-type="bibr" rid="CR48">
      48
     </xref>
     ,
     <xref ref-type="bibr" rid="CR49">
      49
     </xref>
    </sup>
    . Wakati data za CITE-Seq zinazohusu kuonyesha kuwa CAR33- na CAR33-
    <italic>
     KLRC1
    </italic>
    -NK zinatumia mchanjo mizuri ya kusimamia uchafu, ushirikiano wa muda mrefu na muda mfupi wa kusimamia uchafu kwenye zana zinazohusiana na mabadiliko zinazotolewa kwa CAR na zinazotokana kwa kusimamia checkpoint ya NKG2A. Hii inaweza kuwa muhimu kwa uwezo wa zana za kusimamia uchafu kwenye mazingira ya tumor inayopunguza IFN-γ/HLA-E
    <sup/>
    .
   </p>
   <p id="Par24">
    Majaribio yetu ya in vivo hawapopendekeza dozi ya mwisho bora lakini walipatia uwezo wa zana zinazohusiana na mabadiliko zinazotolewa kwa CAR-NK kwa uhusiano wa AML tayari kwa mawasiliano mbili ya dozi madogo ya 3 × 10 zana za NK na uwezo sawa baada ya mawasiliano matatu ya 5 × 10 zana. Data kliniki kutoka kwa majaribio ya CAR-NK ya hivi karibuni kwa uhusiano wa ugonjwa wa B cell walipatia uwezo wa kufanya mabadiliko makubwa kwa dozi madogo za mchakato wa zana
    <sup>
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
    </sup>
    . Hata hivyo, hii linahitaji kujitambuliwa zaidi kwa mabadiliko zinazohusiana na CAR-NK zinazotolewa kwa mabadiliko zinazohusiana na AML mara tatu kwa njia ya kliniki.
   </p>
   <p id="Par25">
    Mabadiliko ya mara mbili kwenye zana za NK zina uwezo mkubwa wa mabadiliko zinazohusiana na CAR-NK zinazobora na zinazotokana na kusimamia mazingira za kusimamia uchafu zinazohusiana na NKG2A. Kama mfano, tuliwa kwa mara nyingi kuwa tuliwa kwa mara moja ya kusimamia protein ya cytokine-inducible Src homology 2–containing (
    <italic>
     CISH
    </italic>
    ) kwenye zana za CAR-NK zinazotolewa kwa damu ya umbili zinaweza kubadilisha "fitness" ya metabolism, upatikanaji wa muda mrefu kwenye binadamu na kusimamia uchafu
    <sup>
     <xref ref-type="bibr" rid="CR49">
      49
     </xref>
    </sup>
    . Hata hivyo, mabadiliko ya gene zinazotolewa kwa checkpoint za kusimamia uchafu zinahitaji kujitambuliwa kwa kutosha kwa kutoa faida zao ya kazi.
   </p>
   <p id="Par26">
    Kuhusu umuhimu wa mazingira ya TIGIT receptor-mediated kwenye zana za NK, tuliwa kwa mara nyingi kuwa kusimamia TIGIT inaweza kubadilisha kazi ya zana za NT-NK lakini si ya CAR-NK kwa uhusiano wa AML
    <sup>
     <xref ref-type="bibr" rid="CR50">
      50
     </xref>
    </sup>
    . Kwa kinyume, tuliwa kwa mara moja ya kusimamia uwezo wa zana zinazohusiana na
    <italic>
     TIGIT
    </italic>
    -knockout-CAR-NK kwa uhusiano wa glioblastoma, ambayo kwa kinyume ina uafaa na matokeo yetu ya
    <italic>
     KLRC1
    </italic>
    kwenye zana za CAR-NK kwa uhusiano wa AML
    <sup>
     <xref ref-type="bibr" rid="CR51">
      51
     </xref>
    </sup>
    .
   </p>
   <p id="Par27">
    Kwa mada ya kliniki mara tatu, njia ya kusimamia gene inahitaji kujitambuliwa kwa kutosha, kwa sababu umuhimu wa mazingira za kusimamia uchafu zinazotolewa kwa virally generated CAR-T cell products ziliwaorodheshwa
    <sup>
     <xref ref-type="bibr" rid="CR52">
      52
     </xref>
    </sup>
    . Kwenye mazingira hii, njia za kusimamia gene zinazotolewa kwa kutosha kwa virus zinaweza kurejelea hatari ya transformation ya kusimamia uchafu kwenye mchakato wa zana za kusimamia uchafu
    <sup>
     <xref ref-type="bibr" rid="CR26">
      26
     </xref>
     ,
     <xref ref-type="bibr" rid="CR53">
      53
     </xref>
     ,
     <xref ref-type="bibr" rid="CR54">
      54
     </xref>
    </sup>
    .
   </p>
   <p id="Par28">
    Kwa umuhimu zote, tulionyesha mara ya kwanza kwamba CAR33-
    <italic>
     KLRC1
    </italic>
    -NK cells yanayoweza kuwa mafanikio sana na salama katika uchanganuzi wa maisha kabla ya kujifunza kwa kawaida. Ubadilishaji wa jeneetiki wa mara mbili kwa kujenga CAR na kusimamia kwa ufaa mizizi ya kutekeleza yanayoweza kujenga uwezo wa NK cells kusimamia matukio ya kutekeleza sio tu ya AML, bali pia ya aina nyingi za kanceri kingine
    <sup/>
    .
   </p>
  </sec>
  <sec id="Sec10" sec-type="methods">
   <title>
    Uchanganuzi
   </title>
   <sec id="Sec11">
    <title>
     Ushahidi wa kihakika
    </title>
    <p id="Par29">
     Zote kazi zinazotumika vifaa vya binadamu zilipatikana rukuni kutoka kwa bao la kuhakikisha kihakika mahitaji (approval no 329/10 na 274/18) na zilifanyika kulingana na masharti ya Helsinki. Kuzitumia vifaa vya maji njaa vilipatikana rukuni kutoka kwa Bao la Kihakika Mahitaji la Hospitali ya Frankfurt (approval No. SHN-12-2016, amend 01 2021 na 02 2022) na uhusiano wa kufanyia utafiti wa leukemia (SAL, approval No. EK98032010). Zote kazi zinazotumika nyuki vilipatikana rukuni kutoka kwa Regierungspräsidium Darmstadt, Germany (FK1123).
    </p>
   </sec>
   <sec id="Sec12">
    <title>
     Sehemu za AML za kwanza
    </title>
    <p id="Par30">
     Vifaa vya maji njaa vilivyotokana kwa wachezaji wa AML vilivyoongezwa katika madini ya IMDM iliyopitishwa na 20% FBS na 1% penicillin/streptomycin na nyuzi zilizotumika kwa dakika 10 na 100 µg/ml DNAse I. Baadaye, nyuzi zilizotokana zilizotokana na madini ya IMDM iliyopitishwa na L-glutamine na HEPES (Invitrogen) iliyopitishwa na 100 U/ml penicillin, 100 mg/ml streptomycin, 100 ng/ml stem cell factor (SCF), 20 ng/ml IL-3, 20 ng/ml IL-6 na 100 ng/ml FMS-like tyrosine kinase 3 ligand (FLT3L). Nyuzi zilizotokana zilizotokana kwa kasi ya 2×10 nyuzi/ml katika sahani ya 12-well. Siku ya pili nyuzi zilizotokana zilizotokana kwa kuchambua kwa kifupi (FSC/SSC) na 7-AAD-staining (BD Biosciences), AML blasts zilizotokana kwa kutumia CD45dim kwa kutumia anti-CD45-APC (Clone 2D1, BD Biosciences), CD33 kwa kutumia anti-CD33-BV421 (Clone WM53, BD Bioscience) na HLA-E kwa kutumia anti-HLA-E-APC (Clone 3D12, Biolegend) antibodies. Siku ya pili baada ya kuzitokana, nyuzi zilizotokana zilizotokana katika utafiti wa kutekeleza wa dakika 4 na NK cells. Kwa maelezo zaidi kuhusu sifa za wachezaji, tazama Supplementary Table
     <xref ref-type="supplementary-material" rid="MOESM1">
      1
     </xref>
     <sup/>
     . Kuzitumia vifaa vya maji njaa vilipatikana rukuni kutoka kwa Bao la Kihakika Mahitaji la Hospitali ya Frankfurt, Germany (approval no. 274/18). Wafanyikazi wote walipatikana rukuni wa kujaza kwa mikakati kulingana na Ujumbe wa Helsinki.
    </p>
   </sec>
   <sec id="Sec13">
    <title>
     Unganishaji wa nyimbo za NK
    </title>
    <p id="Par31">
     Nyuzi za NK zilizotokana kutoka kwa vifaa vya maji njaa vilivyotokana kwa damu ya kijani, wanaotajwa kwa jina kama wanaotajwa na German Red Cross Blood Donation (DRK-Blutspendedienst Baden-Württemberg-Hessen, Frankfurt am Main, Germany) kama ilivyotolewa kwa mara nyingine
     <sup>
      <xref ref-type="bibr" rid="CR55">
       55
      </xref>
     </sup>
     . Kwa maelezo mafupi, nyuzi za damu za kijani (PBMCs) zilizotokana kwa kuzingatia Ficoll density gradient centrifugation (Biocoll, Biochrom) na uwezo wa kuongeza nyuzi za NK zilizotokana kwa kutumia EasySep Human NK Cell Enrichment Kit (StemCell) kulingana na maelezo ya mfanyabiashara. Uwezo wa nyuzi za NK zilizotokana kuzitumika kwa uchanganuzi wa flow cytometry. Hii mradi ulipatikana rukuni kutoka kwa Bao la Kihakika Mahitaji la Goethe University Frankfurt, Germany (approval no. 329/10).
    </p>
   </sec>
   <sec id="Sec14">
    <title>
     Cryopreservation of allogeneic genetically engineered NK cells
    </title>
    <p id="Par32">
     Nyuzi za NK zilizotokana kutoka kwa vifaa vya maji njaa vilizungumzwa kwa 300
     <italic>
      g
     </italic>
     kwa dakika 10. Madini yaliyobakia yalizotokana, na nyuzi yalizotokana kwa madini ya RPMI1640 ya baridi iliyopitishwa na 20% fetal bovine serum (FBS). Baadaye, kasi sawa ya madini ya RPMI1640 iliyopitishwa na 20% Dimethyl sulfoxide (DMSO) ilizotokana kwa kuchanganyika mara kwa mara kwa kuzingatia madini ya nyuzi. Uwezo wa mwisho ulizotokana kati ya (4–16) × 10 nyuzi/ml. Madini ya nyuzi yalizotokana kuzifungwa kwa −80 °C kwa kutumia Mr. Frosty freezing container (Thermo Fisher Scientific). Kwa uchaguzi wa muda mrefu nyuzi yalizotokana kuzitumika kwa nitrogeni ya asili
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec15">
    <title>
     CAR construction and lentiviral vector production
    </title>
    <p id="Par33">
     CAR ya jeneresioni ya pili ya kusimamia CD33 ambayo inajumuisha sekafu ya My96 scFv iliyotumika kama ilivyotolewa kabla
     <sup>
      <xref ref-type="bibr" rid="CR40">
       40
      </xref>
     </sup>
     . Sekafu ya My96 scFv iligunduliwa na kikokotoo cha CD8 na sehemu ya transmembrane, sehemu ya co-stimulatory ya 4-1BB/CD137, na sehemu ya activation ya CD3ζ. Peptidi ya mkuu iliyojiondozwa iliyotolekwa, iliyojumuisha promoter ya EF-1α iliyotokana na GM-CSFRα. Vekotasi vya lentivirus vya self-inactivating vya pseudotyped envelope ya nyani (vya jeneresioni ya tatu) vilizotengenezwa kwa mchakato wa transient transfection kwenye selli za HEK293T kwa kutumia MACSfectin (Miltenyi Biotec) au polyethylenimine (PEI)
     <sup>
      <xref ref-type="bibr" rid="CR56">
       56
      </xref>
      ,
      <xref ref-type="bibr" rid="CR57">
       57
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec16">
    <title>
     Transduction of primary NK cells
    </title>
    <p id="Par34">
     Sellzi za NK ilizotumwa kama ilivyotolewa kabla
     <sup>
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
     </sup>
     . Siku ya pili baada ya kusimamia sellzi za NK, sellzi ziliingizwa na vekotasi vya lentivirus pamoja na Vectofusin-1 (Miltenyi Biotec; 2.5 µg/ml kama umeshikwa). Mchakato wa virus-cells ulizotengenezwa kwa 400
     <italic>
      g
     </italic>
     kwa muda wa 2 saa kwenye 32 °C. Baada ya 24 sa, nusu ya madini ilizoradhiwa na madini mpya. Baada ya kusimamia, sellzi za NK zilizotengenezwa katika madini ya NK-MACS iliyopunguzwa na 5% plasma ya binadamu, 1% NK-MACS Supplements, 1% Pen/Strep, 500 IU/ml IL-2 (Miltenyi Biotec au Novartis) na 10 ng/ml IL-15 (Miltenyi Biotec) au 50 ng/ml IL-15 (CellGenix)
     <sup>
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="CR57">
       57
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec17">
    <title>
     <italic>
      KLRC1
     </italic>
     -targeting CRISPR/Cas9 nucleases
    </title>
    <p id="Par35">
     Sellzi za NK za kwanza zilizotengenezwa kwa kutumia mfumo wa CRISPR/Cas9 ya kubadilika kwa kasi kama ilivyotolewa hivi karibuni
     <sup>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
     </sup>
     . Kwa njia ya kisa, 1 × 10 sellzi za NK zilizotengenezwa (IL-2 + IL-15) zilizotumwa (NT)-NK au CD33-directed CAR (CAR33)-NK zilizotumwa (4D-Nucleofector; Lonza) baada ya siku moja kwa muda wa siku moja au mchakato wa ziada kwa kutumia miaka ya Cas9:gRNA kulingana na mfumo wa NK cell nucleofection uliyotolewa kwa kasi
     <sup>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ,
      <xref ref-type="bibr" rid="CR53">
       53
      </xref>
     </sup>
     . Sellzi zilizotengenezwa kwa 1 × 10 selli/ml katika madini ya 500 µL. Sellzi za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK na sellzi za kudhibiti zilizotengenezwa kwa siku 10 kwa muda wa siku 10 baada ya nucleofection kabla ya kujitolea katika majaribio ya kazi ya kifiziki au kwenye mlo
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec18">
    <title>
     Genotyping of edited NK cells
    </title>
    <p id="Par36">
     Genotyping ya sellzi za NK zilizotumwa kwa
     <italic>
      KLRC1
     </italic>
     ilizotengenezwa kwa kutumia T7 endonuclease I (T7E1, NEB) na kwa kutumia Inference of CRISPR Edits (ICE) analysis (Synthego Performance Analysis, ICE Analysis. 2019. V3.0). PCR amplicon ya 421 bp iliyohusu mstari wa matokeo ulizotengenezwa kwa kutumia primer pair (5′-ctccacctcacccttttaattg-3′ na 5′-caacttggaattctgatctttgc-3′), ilizotambuliwa na kuzitumika kwa T7E1 kama ilivyotolewa kabla, ambayo ilizotofautisha bandi za 228 bp na 193 bp, kwa kawaida na/au kuzitumika kwa Sanger sequencing ili kuchambua tofauti za indels mara moja kwenye mstari wa matokeo kwa ICE analysis. Data zetu zilizorudi kuzisikia kuzingatia ya matokeo ya wild-type katika sampuli zilizotumwa kwa kasi kulingana na zilizotumwa kwa kasi. Hata hivyo, kuzisikia 100% kwa ufanisi wa kubadilisha kulingana na maelekezo ya ICE analysis ilikuwa si kazi. Kwa khusus, ICE analysis ina ufanisi mkubwa kwa ubora wa matokeo ya Sanger sequencing, hivyo jumla ya sambazuri za indel zinatengeneza anwani ya R2 na matokeo zinazobaki zinazetolewa kama sehemu za kubadilishwa. Uchambuzi wa kawaida wa sambazuri za kubadilisha ilizotengenezwa kwa targeted amplicon next-generation sequencing (NGS) kwa kutumia primer pair uliyohusu mstari wa matokeo wa
     <italic>
      KLRC1
     </italic>
     (5′-acctgaatctgcccccaaac-3′ na 5′-ccaagctgcacatcctagac-3′)
     <sup>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      <xref ref-type="bibr" rid="CR58">
       58
      </xref>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
     </sup>
     . Paired-end reads zilizotambuliwa kwa kutumia version ya command line ya CRISPResso2.
    </p>
   </sec>
   <sec id="Sec19">
    <title>
     Flow cytometry analysis
    </title>
    <p id="Par37"/>
   </sec>
   <sec id="Sec20">
    <title>
     CAR-NK cell functional assay
    </title>
    <p id="Par38">
     Matumizi ya mwisho ya kusimamia uchafu kati ya muda wa 4 au 24 saa ya kusimamia kwa sambamba au sambamba iliyohifadhiwa (NT)-,
     <italic>
      KLRC1
     </italic>
     -, CAR33- au CAR33-
     <italic>
      KLRC1
     </italic>
     -NK ziliangazwa kwa flow cytometry. Kwa hiyo, zana zinazohifadhiwa au zinazotabiriwa na GFP au zinazotabiriwa na Cell Trace CFSE proliferation kit (Invitrogen) zilikuwa zinazikusimamia na zana za kusimamia kwa nisabu mbalimbali za mzunguko (E:T) kwa muda uliotoa kwa muda ya 37 °C na 5% CO
     <sub>
      2
     </sub>
     <sup/>
     . Baada ya hayo, zana zilizitabiriwa na 4’,6-Diamidino-2-phenylindole (DAPI) (AppliChem) na uwezekano wa zana zilizotabiriwa uliyangalizwa kwa BD FACSCelesta (BD Biosciences). Kusimamia uchafu kwa muda halisi, mfumo wa IncuCyte S3 wa kusimamia zana za kizazi (Sartorius) ulitumika kulingana na Incucyte Annexin V Dye Product Guide. Tabla ya 96-kikuu ya kikuu ya kikuu iliilipatikana kwa 5 µg/ml fibronectin (Sigma-Aldrich) iliyotengenezwa kwa 0.1% BSA. Kusimamia kifoofu katika video, IncuCyte Annexin V Red Dye (Sartorius) iliyotengenezwa kwa 1 mM CaCl
     <sub>
      2
     </sub>
     kwa nisabu ya 2.5 µM. Zana za GFP OCI-AML2 zilikuwa zinazikusimamia na zana za kusimamia kwa nisabu za E:T ya 0.5:1, 1:1 au 2.5:1. Picha zilipatikana kila dakika 30 kwa 10x magnification
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec21">
    <title>
     Cytometric bead array
    </title>
    <p id="Par39">
     Matumizi ya cytokine ya NT-,
     <italic>
      KLRC1
     </italic>
     -, CAR33- au CAR33-
     <italic>
      KLRC1
     </italic>
     -NK zinazokusimamia na zana za AML au zana za AML za kizazi, kama vile matumizi ya cytokine katika damu kutoka kwa NSG-SGM3 mice zinazotumika zana za NK, zililalamishwa kwa BD Cytometric Bead Array (CBA; BD Biosciences) kama ilivyotolewa kwa mbele
     <sup>
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec22">
    <title>
     Cell preparation for qPCR and western blot analysis
    </title>
    <p id="Par40">
     NT-,
     <italic>
      KLRC1
     </italic>
     -, CAR33- au CAR33-
     <italic>
      KLRC1
     </italic>
     -NK zilikuwa zinazikusimamia na zana za OCI-AML2 kwa nisabu ya E:T ya 3:1 kwa muda wa 2 saa kwa NK-MACS medium iliyotengenezwa kwa 5% damu ya binadamu, 1% NK-MACS Supplements, 1% Pen/Strep na 500 U/ml IL-2 (Miltenyi Biotec au Novartis). Baada ya hayo, zana zilizitabiriwa na 7-AAD (BD Biosciences) na zilizotambuliwa kwa BD FACSAria Fusion device (BD Biosciences). Zana za NK zilizotambuliwa kwa GFP/7-AAD na zana za OCI-AML2 zilizotambuliwa kwa GFP/7-AAD
     <sup/>
     . Mwishowe, zana zilizipinduzwa, na zana zilizipunguza zilizifungwa kwa −80 °C kwa matumizi zaidi ya qPCR au western blot. Kama mfano, zana za OCI-AML2 zilizotengenezwa peke yake na kutoka kwa aina yoyote ya zana, zana zilizipinduzwa, na zana zilizifungwa kwa −80 °C bila kusimamia.
    </p>
   </sec>
   <sec id="Sec23">
    <title>
     Relative mRNA quantification
    </title>
    <p id="Par41">
     RNA iliyotengenezwa kwa peqGOLD MicroSpin total RNA kit kulingana na mfano (PEQLAB Biotechnologie GmbH). Matumizi ya RNA iliyohusika na hatua ya DNaseI digestion ya kwenye column (PEQLAB Biotechnologie GmbH). Matumizi ya cDNA iliyotengenezwa kwa RevertAid first strand cDNA synthesis kit (ThermoFisher), kwa kiasi kawaida cha 1 µg ya RNA kwa kila mfano. qRT-PCR iliyotumika kwa QuantStudio Flex 7 qRT-PCR cycler (Applied Biosystems) kwa kuzingatia Sybr Green PCR master mix (Applied Biosystmes). Kwa matumizi ya primer zingezoe Supplementary Table
     <xref ref-type="supplementary-material" rid="MOESM1">
      3
     </xref>
     <sup/>
     . Matumizi ya RNA transcripts iliyotengenezwa kwa kuzingatia usimamizi wa ΔΔCq kama ilivyotolewa kwa mbele
     <sup>
      <xref ref-type="bibr" rid="CR59">
       59
      </xref>
      ,
      <xref ref-type="bibr" rid="CR60">
       60
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec24">
    <title>
     Western blot
    </title>
    <p id="Par42">
     Matumizi ya protein expression levels iliyotengenezwa kwa zana za kizazi zote, zana zilizotengenezwa kwa Triton-X buffer (30 mM Tris pH [7.4], 150 mM NaCl, 1% Triton-X, 10% glycerol, 0.5 mM PMSF, 2 mM DTT, 1x protease inhibitor cocktail (Roche)). Antibodies zifuatazo zilizotumika kwa Western blot detection: rabbit anti-Caspase-3 (Cell Signaling, 9662S), mouse anti-Caspase-8 (Enzo, ADI-AAM-118-E), mouse anti-PARP (poly(ADD)ribose polymerase) (Cell Signaling, 9546S), mouse anti-GAPDH (glyceraldehyde 3-phosphate dehydrogenase) (BioTrend, 5G4-6C5), rabbit anti-Caspase-9 (Cell Signaling, 9502S), goat anti-mouse (Abcam, ab6789), goat anti-rabbit (Abcam, ab6721). Antibodies za mara ya pili zilizotengenezwa kwa horseradish peroxidase, na alama iliyotengenezwa kwa enhanced chemiluminescence detection substrate (ThermoFisher). Zingezoe orodha yote ya antibodies katika Supplementary Table
     <xref ref-type="supplementary-material" rid="MOESM1">
      2
     </xref>
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec25">
    <title>
     Cell preparation for CITE-seq analysis
    </title>
    <p id="Par43">
     Kwa analizi ya sekondingi ya nyaraka kwa nyaraka, zana za NK (zilizofanyika mabadiliko genetiki) zilizotokwa kutoka kwa wateja wawili na wawili wamegunduliwa na kuzingatia kwa 2 × 10 zana/ml kwenye tabia ya 48-well katika 750 µl katika madhania ya NK-MACS iliyopitishwa kwa 1% NK-MACS Supplements, 5% damu ya binadamu, 1% Pen/Strep, 500 U/ml IL-2 (Miltenyi Biotec au Novartis) na pia 50 ng/ml IL-15 (CellGenix) kwa kila well. Baada ya siku tatu zana ziliingwa na zilizitumika kwenye uchumi na zana za OCI-AML2 katika sahani za 6 cm kwa nisaba ya E:T ya 1:1. Zana za OCI-AML2 ziliingwa kwa maelezo ya kifaa cha Cell Trace CFSE proliferation kit (Invitrogen) kulingana na maelezo ya kifaa. Kama mfano, zana za NK ziliingwa bila kuwasiliana na zana za AML. Baada ya dakika 2 zana zilizokwenda ziliingwa, na kufanyika Fc-block kwa kutumia mafuta ya hIgG (Kiovig na Intratect, Chuo Kikuu cha Frankfurt). Baada ya hivyo, zana ziliingwa kwa mafuta ya anti-NKG2A-PE (Clone Z199, Beckman Coulter), CD33-CAR-detection reagent (CD33-protein-biotin + anti-biotin-APC (Clone RE746, Miltenyi Biotec) kulingana na aina ya zana na kila sharti iliyotolewa kwa SampleTag tofauti kutoka kwa human Single Cell Sample Multiplexing Kit (BD Biosciences). Baada ya hivyo, zana ziliingwa kwa 7-AAD (BD Biosciences) ili kusambaza zana zilizomarisha na ziliingwa kwa BD FACSAria machine. Zana za NK ziliingwa kama ifuatayo: NT-NK kama CFSE,
     <italic>
      KLRC1
     </italic>
     -NK kama CFSE/NKG2A, CAR33-NK kama CFSE/CAR na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK zana kama CFSE/NKG2A/CAR zana. Baada ya hivyo, sekondingi ya nyaraka kwa nyaraka ilifanyika kwa kutumia BD Rhapsody Single-cell analysis system (BD Biosciences)
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec26">
    <title>
     Single-cell cellular indexing of transcriptomes and epitopes by sequencing (CITE-Seq)
    </title>
    <p id="Par44">
     Kwa analizi ya sekondingi ya transcriptomes na epitopes, zana zilizotolewa ziliingwa kwenye 5 ml FACS tube, ili kuchunguza idadi ya zana sawa kutoka kwa kila wateja na kila sharti. Zana ziliingwa mara moja na baada ya hivyo ziliingwa kwenye 100 µL Stain Buffer (BSA) (BD Biosciences, cat# 554657). Baada ya hivyo, zana ziliingwa kwa mafuta ya master mix yanayopita 2 μL ya kila mafuta ya 49 BD AbSeq oligonucleotide-conjugated (BD Biosciences; tazama Supplementary Table
     <xref ref-type="supplementary-material" rid="MOESM1">
      4
     </xref>
     ) kwa dakika 40 kwenye barafu. Baada ya kuhifadhi mara mbili kwa BD Stain Buffer, zana ziliingwa kwenye 620 μL BD sample buffer (BD Biosciences, cartridge reagent kit, cat# 633731). Mafuta ya zana ziliingwa kwa 3.1 μL 2 mM Calcein AM (BD Biosciences, cat# 564061) na 3.1 μL Draq7 (BD Biosciences, cat# 564904) kwa dakika 5 kwenye joto ya 37 °C katika giza. Uhusiano wa zana na maisha yaliangalia kwa kutumia 10 µL ya mafuta ya zana zilizoyingwa kwenye disposable hemocytometer (Incyto, cat# DHC-N01-5) na BD Rhapsody Scanner. Mafuta ya zana yanayopita 40,000 zana zilizoyingwa ziliingwa na ziliingwa mara moja kwenye BD Rhapsody cartridge (BD Biosciences, cat# 633733) kulingana na maelezo ya kifaa. Mafuta yanayopita oligonucleotide-labeled capture beads ziliingwa kwenye cartridge na zana ziliingwa kwa mafuta ya lysing buffer yanayopita 5 mM DTT. Mafuta yanayopita mRNA, Sample Tags na oligonucleotide-labeled antibodies ziliingwa na ziliingwa mara moja kabla ya kufanyika reverse transcription na exonuclease I treatment (BD Biosciences, cDNA kit, cat# 633773). DNA libraries ziliingwa kwa kutumia BD Rhapsody targeted mRNA and AbSeq amplification kit (BD Biosciences, cat# 633774). Kwa hiyo, human Immune Response Targeted Panel (BD Biosciences, cat# 633750) iliyotolewa kulingana na primer panel iliyotolewa kwa maelezo ili kufanya amplify cDNA ya 434 genes tofauti (tazama Supplementary Table
     <xref ref-type="supplementary-material" rid="MOESM1">
      5
     </xref>
     ) kulingana na maelezo ya kifaa. Uhusiano wa DNA libraries yanayopita indexes ya Illumina sequencing yaliangalia kwa kutumia Qubit 4 Fluorometer kwa High Sensitivity dsDNA kit (ThermoFisher Scientific, cat# Q32851) na Agilent 4150 Tapestation kwa High Sensitivity D1000 screentape (Agilent, cat# 5067-5584, 5067-5585). Libraries ziliingwa mara moja kwa uhusiano wa 1 nM na ziliingwa mara moja kwa 20 % PhiX DNA kwa mara nyingi (75 bp paired-end) kwenye NextSeq2000 sequencer (Illumina).
    </p>
   </sec>
   <sec id="Sec27">
    <title>
     Single-cell cellular indexing of transcriptomes and epitopes by sequencing (CITE-Seq) data analysis
    </title>
    <p id="Par45">
     Mafuta yanayopita FASTQ ziliingwa mara moja pamoja na maelezo ya panel ya mRNAs na AbSeqs kwenye platform ya SevenBridges (Seven Bridges Genomics,
     <ext-link ext-link-type="uri" href="https://www.sevenbridges.com">
      https://www.sevenbridges.com
     </ext-link>
     ) na ziliingwa kwa kutumia BD Rhapsody analysis pipeline (BD Biosciences) kulingana na maelezo ya kifaa. Kwa hiyo, mafuta yanayopita low-quality read pairs ziliingwa na mafuta yanayopita R1 ziliingwa kwa cellular barcode na unique molecular identifier (UMI)s. Mafuta yanayopita R2 ziliingwa kwa maelezo ya reference transcript sequences na mafuta yanayopita identical cell label, UMI sequence na reference gene ziliingwa kwa mafuta yanayopita single molecule. Baada ya hivyo, algorithm yanayopita recursive substitution error correction (RSEC) ziliingwa kulingana na maelezo ya kifaa. Kwa mwisho, cell counts ziliingwa na Sample Tags ziliingwa kwa zana kulingana na kutoa RSEC-adjusted molecule count matrices.
    </p>
   </sec>
   <sec id="Sec28">
    <title>
     Input data structure
    </title>
    <p id="Par46"/>
   </sec>
   <sec id="Sec29">
    <title>
     Preprocessing workflow
    </title>
    <p id="Par47"/>
   </sec>
   <sec id="Sec30">
    <title>
     Studying the effect of CAR33 and
     <italic>
      KLRC1
     </italic>
     -KO on NK cells on transcript and surface marker expression before co-culture with AML cells
    </title>
    <sec id="Sec31">
     <title>
      Differential gene expression analysis
     </title>
     <p id="Par48">
      Uhusiano wa data kwenye viwango vilivyoundwa vya wateja D1 na D2 ilifanyika kwa kina kwa kina kwa RNA na vitabu vya ADT. Tulipatikana mwendo wa pseudo-bulk, ambapo tulizungumza vitambulisho vya sifa kulingana na masharti (NT-NK,
      <italic>
       KLRC1
      </italic>
      -NK, CAR33-NK na CAR33-
      <italic>
       KLRC1
      </italic>
      -NK cells) na wateja (D1 na D2). Kwa maambukizi ya RNA na ADT, tuliamua
      <italic>
       edgeR
      </italic>
      na
      <italic>
       limma
      </italic>
      , kwa kina kwa kina
      <sup>
       <xref ref-type="bibr" rid="CR64">
        64
       </xref>
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
      </sup>
      .
     </p>
     <p id="Par49">
      Tulimipimisha matrisi ya model kulingana na masharti maalum (kwa kutumia formula ya mifano: ~donor + CAR + KO + CAR:KO). Kwa RNA, tulifitisha model ya quasi-likelihood negative binomial generalized log-linear kwa data ya vitambulisho, na tulitathmini maambukizi ya transcripti kulingana na thamani ya fold-change iliyotolewa (=log2(1.2)) kwa kutumia
      <italic>
       glmQLFit
      </italic>
      na
      <italic>
       glmTreat
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR64">
        64
       </xref>
       <xref ref-type="bibr" rid="CR64">
        64
       </xref>
      </sup>
      . Kwa ADT, tulipindua data ya vitambulisho kwa log2-counts per million (logCPM) kwa kutumia
      <italic>
       voom
      </italic>
      , na tulifitisha model ya linear kwa kila sifa kwa kutumia
      <italic>
       lmFit
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
      </sup>
      . Baada ya hivyo, metodo ya empirical Bayes na funksi ya
      <italic>
       treat
      </italic>
      iliyotumika kusindika maambukizi ya sifa za kifupi kulingana na thamani ya fold-change ya log2 (1.05)
      <sup>
       <xref ref-type="bibr" rid="CR61">
        61
       </xref>
       <xref ref-type="bibr" rid="CR66">
        66
       </xref>
       ,
       <xref ref-type="bibr" rid="CR67">
        67
       </xref>
      </sup>
      . Mwishowe, kwa kila mifano, sifa za RNA na ADT zote zilizoratibuwa kulingana na thamani ya
      <italic>
       p
      </italic>
      -value au thamani ya fold change ya logarithmic (logFC) na zilizafanana kama zilizozidi au zilizopungua kwa kutumia
      <italic>
       decideTests
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
      </sup>
      . Tulipatikana matokeo yetu katika volcano (
      <italic>
       ggplot2
      </italic>
      ) na dot plots (
      <italic>
       scater
      </italic>
      ) wakishiriki sifa maalum za kujihusisha
      <sup>
       <xref ref-type="bibr" rid="CR68">
        68
       </xref>
       <xref ref-type="bibr" rid="CR61">
        61
       </xref>
       ,
       <xref ref-type="bibr" rid="CR63">
        63
       </xref>
      </sup>
      .
     </p>
    </sec>
    <sec id="Sec32">
     <title>
      Single-cell analysis
     </title>
     <p id="Par50">
      Baada ya kujifunza athari ya jumla ya kila moja kati ya masharti matatu kwenye mwendo wa pseudo-bulk, tuliandaa tathmini zaidi za kujihusisha kwenye nyuzi kabla ya co-culture kwenye mwendo wa nyuzi moja. Wateja wawili D1 na D2 walianalizwa kwa kina kwa kina.
     </p>
    </sec>
    <sec id="Sec33">
     <title>
      Data processing and clustering
     </title>
     <p id="Par51">
      Vitambulisho vilivyoundwa vya ADT na RNA vilivyngeundwa vilivyngeundwa kwa kujumlisha kwenye matriksi moja ya sifa. Analizi ya kifupi ya kawaida (PCA) ilifanyika kwa 20 components kabla ya clustering ya Louvain
      <sup>
       <xref ref-type="bibr" rid="CR69">
        69
       </xref>
       ,
       <xref ref-type="bibr" rid="CR70">
        70
       </xref>
       ,
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
       ,
       <xref ref-type="bibr" rid="CR72">
        72
       </xref>
      </sup>
      . Thamani mbalimbali za parameter
      <italic>
       k
      </italic>
      , ambayo inatafsiriwa kama namba ya jirani, iliyotestwa na iliyoevaluwa kwa kutumia anwani za usimilarity za clustering (adjusted rand index (ARI) &amp; weighted rand index (WRI)). Matokeo ya clustering ya Louvain yenye
      <italic>
       k
      </italic>
      = 50 ilirudia namba ya kawaida ya clusters na ilipata anwani ya juu zaidi katika anwani zote za usimilarity (Supplementary Fig.
      <xref ref-type="supplementary-material" rid="MOESM1">
       S3c
      </xref>
      ) na ilitumika katika tathmini za chini. Matokeo yote yalipatikana kwenye t-distributed stochastic neighbor embedding (t-SNE)
      <sup>
       <xref ref-type="bibr" rid="CR73">
        73
       </xref>
      </sup>
      .
     </p>
    </sec>
   </sec>
   <sec id="Sec34">
    <title>
     Studying the effect of co-culture on transcript and surface marker expression following co-culture with AML
    </title>
    <p id="Par52">
     Baada ya kujifunza athari ya
     <italic>
      KLRC1
     </italic>
     , CAR33 na ushirikiano wao pamoja, tulitaka kujifunza mabadiliko ya gene na sifa za kifupi baada ya co-culture ya AML. Tulijumlisha data zote zote kutoka kwa D1 na D2 bila kuzungumza nyuzi kulingana na co-culture ya AML. Hii ilirudia kujivyo nyuzi kabla ya co-culture na nyuzi baada ya co-culture. Kwa jumla, tulikuwa na 53,105 nyuzi, ambazo 29,607 ilikuwa iliyoco-culture na AML-cells. Tulipatikana mwendo wa pseudo-bulk, ambapo tulizungumza vitambulisho vya sifa kulingana na kabla/baada ya co-culture, masharti (NT-NK,
     <italic>
      KLRC1
     </italic>
     -NK, CAR33-NK na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK cells) na wateja (D1 na D2)
     <sup/>
     .
    </p>
    <sec id="Sec35">
     <title>
      Differential gene expression
     </title>
     <p id="Par53">
      Tulikuandika matriki ya mada yetu kwa majukumu tofauti kutumia formula ya mada: ~ coculture + CAR + KO + CAR:KO. Kutoka hapa, tukamaliza mchakato unaoelezea katika sehemu ya mada “Studying the effect of CAR33 and KLRC1-KO on NK cells”. Pia, tuliamua funksi ya
      <italic>
       scran
      </italic>
      ’s
      <italic>
       find Markers
      </italic>
      ili kutathmini sifa zinazotofautiana katika kila majukumu baada ya co-culture. Tulihesabi logFC values ya RNA na ADT features kwa kila majukumu baada ya co-culture wakati kuliungana na majukumu hayo kabla ya co-culture. Hii iliyotumika ili kutathmini athari za co-culture kwa majukumu mara kwa mara, hasa kuliko athari kubwa ambayo yanayonyeshwa katika grafu za zamani. Matokeo yameonyeshwa katika heatmap
      <sup>
       <xref ref-type="bibr" rid="CR68">
        68
       </xref>
      </sup>
      <sup/>
      .
     </p>
    </sec>
    <sec id="Sec36">
     <title>
      Single-cell analysis
     </title>
     <p id="Par54">
      Baada ya kuelewa athari kubwa za co-culture kwa mada ya pseudo-bulk, tulitaka kuelewa hayo kwa mada ya single-cell. Kama tofauti ya mchakato wetu wa pseudo-bulk, tulitumia nyuzi zinazofuata baada ya co-culture katika mchakato wa single-cell wetu na tulitathmini kwa wakati mbili D1 na D2 kwa kasi kasi ili kuhakikisha usimamizi wa batch-effect. Hii ilikujumuisha 18,604 na 11,003 nyuzi kutoka kwa D1 na D2, kwa kasi kasi.
     </p>
    </sec>
    <sec id="Sec37">
     <title>
      Data processing
     </title>
     <p id="Par55">
      Kama tofauti ya mchakato wa single-cell wa zamani, PCA ilihesabiwa na 20 components na Louvain clustering ilifanyika kwenye values zinazomeingana za ADT na RNA kutumia
      <italic>
       scran
      </italic>
      na
      <italic>
       k
      </italic>
      = 50, na
      <italic>
       igraph
      </italic>
      <sup/>
      . Matokeo yameonyeshwa katika t-SNE map. Matumizi machache ya ushirikiano kwa sifa zinazoweza kutoa kumbukumbu kati ya kumbi zilihesabiwa kutumia
      <italic>
       scoreMarkers
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR72">
        72
       </xref>
       ,
       <xref ref-type="bibr" rid="CR73">
        73
       </xref>
      </sup>
      . Thamani za expression za sifa zinazoweza kutoa kumbukumbu kulingana na mean ya Area Under the Curve (AUC) ya kumbi ya kujihusisha yameonyeshwa katika dot plot kwa kila kumbi.
     </p>
    </sec>
   </sec>
   <sec id="Sec38">
    <title>
     In vivo functional studies of CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK cells in xenografted mice
    </title>
    <p id="Par56"/>
   </sec>
   <sec id="Sec39">
    <title>
     Statistical analysis
    </title>
    <p id="Par57"/>
   </sec>
   <sec id="Sec40">
    <title>
     Reporting summary
    </title>
    <p id="Par58"/>
   </sec>
  </sec>
 </body>
 <back>
  <ack>
   <title>
    Acknowledgements
   </title>
   <p>
    Waziri wamefurahia wafanyabiashara wote waliyoyasumbua kwa maelezo ya kusumbua nyimbo za leukapheresis. Waziri wamefurahia Ralf Schubert kwa usimamizi wa CBA analysis, na Petra Dinse, Petra Schoen, Bernd Lecher, Simone Maurer, Beate vom Hövel, Daniela Brücher, Katja Stein, Franziska Ganß kwa usimamizi wao wa kizazi kizuri, Lea Knapp kwa usimamizi wa majaribio, Sarah Mertlitz kwa msaada wa kujenga picha za confocal microscopy, na wanaomimikana wa jamii ya GSH animal facility na FCI immunmonitoring platform kwa usimamizi wa majaribio, na Christian Brandts kwa usimamizi wa UCT Biobank uliyotumia nyimbo za AML. Tumefurahia Lisa Marie Reindl kwa mazungumzo yanayofaa. Pia, tumefurahia wanaomimikana wa ushirikiano wa kiindustri ya BD Bioscience, Sartorius, PerkinElmer, Revvity na Miltenyi Biotec kwa usimamizi wao wa kizazi kizuri katika matumizi ya teknolojia. Kazi hii iliyosimamishwa na Stiftung Deutsche Krebshilfe (German Cancer Aid) katika majaribio ya kizazi (#70114124 kwa E.U., M.V.) katika maelezo ya programu ya Translational Oncology (#70114180 kwa N.A., E.U.) na ya “CAR FACTORY” (#70115200 kwa E.U., T. Ca.), na Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) katika maelezo ya SFB/IRTG 1292 (Project-ID 318346496 kwa E.U., N.A., L.B.) na majaribio ya kizazi RI 2462/9-1 na RI 2462/10-1 (kwa M.A.R), na CA 311/7-1 (kwa T.Ca.), na Jose Carreras Leukemia Foundation (kwa E.U., O.P., M.A.R. kwa DJCLS 11R/2020, 23R/2021 na DJCLS 15R/2023), na Deutsche Kinderkrebsstiftung DKS_2023_01 (kwa M.V.), na jamii ya “Hilfe für krebskranke Kinder Frankfurt e.V.” katika maelezo ya C
    <sup>
     3
    </sup>
    OMBAT-AML consortium (kwa J.-H.K., R.B., E.U.); na LOEWE Center Frankfurt Cancer Institute (FCI, Hessen State Ministry for Higher Education, Research and the Arts, III L 5 − 519/03/03.001). T.B. aliyosimamishwa na DFG, INDEEP Clinician Scientist Program (Project-ID 493624332), T.B., K.I., S.W. na A.A. aliyosimamishwa na MSNZ Frankfurt (German Cancer Aid), na H.M.R. aliyosimamishwa na Egyptian Ministry of Higher Education kwa usimamizi wa scholarship ya post-doctoral ya mwezi sita katika jamii ya O.P., Charite University Berlin, Germany. Figurasi zimeundwa kwa kutumia BioRender CC-BY license (Figs.
    <xref ref-type="fig" rid="Fig1">
     1
    </xref>
    a,
    <xref ref-type="fig" rid="Fig2">
     2
    </xref>
    a,
    <xref ref-type="fig" rid="Fig5">
     5
    </xref>
    a
    <xref ref-type="fig" rid="Fig6">
     6a
    </xref>
    , mara nyingi katika Figs.
    <xref ref-type="fig" rid="Fig7">
     7
    </xref>
    a,
    <xref ref-type="fig" rid="Fig7">
     7
    </xref>
    e,
    <xref ref-type="fig" rid="Fig7">
     7
    </xref>
    h, na Supplementary Fig.
    <xref ref-type="supplementary-material" rid="MOESM1">
     2a
    </xref>
    ).
   </p>
  </ack>
  <sec sec-type="author-contribution">
   <title>
    Author contributions
   </title>
   <p>
    T.B., N.A., L.B., P.W., A.G., V.S., J.A. H.M.R., B.A.J. wameundaa majaribio; A.G. aliyosimamisha na A.A., K.I. wameandaa data ya CITE-seq. V.S., M.V. wameandaa data ya qPCR. S.W. aliyotoa data ya kliniki. N.A., T.B., L.B. wameandaa data zote. E.U., K.I., N.A., T.B. wameandaa na kumshirikisha kwa maelezo; N.A., T.B., A.A., K.I. wameandaa tathmini ya takwimu; E.U., K.I., R.B., T.O., J.-H.K., O.P., M.A.R., T.Ca.; N.M., M.V. wameandaa mazungumzo pamoja na waziri wote wanaomimikana. T.B., N.A., K.I., E.U. wameandaa maelezo ya kazi pamoja na waziri wote wanaomimikana.
   </p>
  </sec>
  <sec sec-type="peer-review">
   <title>
    Ushauri wa wanaojulikana
   </title>
   <sec id="FPar1">
    <title>
     Ushauri wa wanaojulikana
    </title>
    <p id="Par59">
     <italic>
      Nature Communications
     </italic>
     thanks May Daher, Naval Daver, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.
    </p>
   </sec>
  </sec>
  <sec>
   <title>
    Uwekezaji
   </title>
   <p>
    Open Access funding enabled and organized by Projekt DEAL.
   </p>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Ufikiaji wa data
   </title>
   <p>
    All sequencing data concerning CITE-seq experiments has been deposited in the NCBI GEO repository under accession number
    <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE221552">
     GSE221552
    </ext-link>
    .
    <xref ref-type="sec" rid="Sec42">
     Source data
    </xref>
    are provided with this paper.
   </p>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Ufikiaji wa programu
   </title>
   <p>
    All code used to analyze CITE-seq data is available in the following github repository:
    <ext-link ext-link-type="uri" xlink:href="https://github.com/AGImkeller/CD33_NK_cells_2022">
     https://github.com/AGImkeller/CD33_NK_cells_2022
    </ext-link>
    .
   </p>
  </sec>
  <sec sec-type="ethics-statement">
   <sec id="FPar2" sec-type="COI-statement">
    <title>
     Ushindani wa makusudi
    </title>
    <p id="Par60">
     E.U. has a sponsored research project with Gilead and BMS and acts as medical advisor of Phialogics and CRIION. T.O. has disclosures to Merck KGaA: Honoraria; Gilead: Research Funding; Merck KGaA: Research Funding; Roche: Honoraria. O.P. has received honoraria or travel support from Astellas, Gilead, Jazz, MSD, Neovii Biotech, Novartis, Pfizer, and Therakos, he has received research support from Gilead, Incyte, Jazz, Neovii Biotech, and Takeda and is member of advisory boards to Jazz, Gilead, MSD, Omeros, Priothera, Shionogi, and SOBI. N.M. is employee of Miltenyi Biotec. T.B., P.W., E.U. have filed patents on data partly published in this manuscript: PCT/EP2024/060767: Treatment of leukemia with engineered immune checkpoint inactivated CAR-NK cells and CAR-T cells (U31175WO). No competing interests exists for the remaining authors.
    </p>
   </sec>
  </sec>
  <ref-list id="Bib1">
   <title>
    Viambatilisho
   </title>
   <ref-list>
    <ref id="CR1">
     <label>
      1.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Albinger
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <name>
        <surname>
         Hartmann
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Ullrich
        </surname>
        <given-names>
         E
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
      </article-title>
      <source>
       Gene Ther.
      </source>
      <year>
       2021
      </year>
      <volume>
       28
      </volume>
      <fpage>
       513
      </fpage>
      <lpage>
       527
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXntVOrsL8%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       33753909
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8455322
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41434-021-00246-w
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR2">
     <label>
      2.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Maude
        </surname>
        <given-names>
         SL
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2018
      </year>
      <volume>
       378
      </volume>
      <fpage>
       439
      </fpage>
      <lpage>
       448
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1cXitlylsLw%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       29385370
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5996391
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa1709866
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR3">
     <label>
      3.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Munshi
        </surname>
        <given-names>
         NC
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Idecabtagene vicleucel in relapsed and refractory multiple myeloma
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2021
      </year>
      <volume>
       384
      </volume>
      <fpage>
       705
      </fpage>
      <lpage>
       716
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXlt1KgsLY%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       33626253
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa2024850
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR4">
     <label>
      4.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bouchkouj
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       FDA approval summary: brexucabtagene autoleucel for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
      </article-title>
      <source>
       Oncologist
      </source>
      <year>
       2022
      </year>
      <volume>
       27
      </volume>
      <fpage>
       892
      </fpage>
      <lpage>
       899
      </lpage>
      <pub-id pub-id-type="pmid">
       35983953
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9526496
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/oncolo/oyac163
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR5">
     <label>
      5.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Maude
        </surname>
        <given-names>
         SL
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Chimeric antigen receptor T cells for sustained remissions in leukemia
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2014
      </year>
      <volume>
       371
      </volume>
      <fpage>
       1507
      </fpage>
      <lpage>
       1517
      </lpage>
      <pub-id pub-id-type="pmid">
       25317870
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4267531
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa1407222
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR6">
     <label>
      6.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Liu
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2020
      </year>
      <volume>
       382
      </volume>
      <fpage>
       545
      </fpage>
      <lpage>
       553
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXjtlCgtro%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       32023374
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7101242
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa1910607
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR7">
     <label>
      7.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Marin
        </surname>
        <given-names>
         D
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
      </article-title>
      <source>
       Nat. Med.
      </source>
      <year>
       2024
      </year>
      <volume>
       30
      </volume>
      <fpage>
       772
      </fpage>
      <lpage>
       784
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXhvFantrg%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       38238616
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10957466
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41591-023-02785-8
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR8">
     <label>
      8.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Döhner
        </surname>
        <given-names>
         H
        </given-names>
       </name>
       <name>
        <surname>
         Weisdorf
        </surname>
        <given-names>
         DJ
        </given-names>
       </name>
       <name>
        <surname>
         Bloomfield
        </surname>
        <given-names>
         CD
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Acute myeloid leukemia
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2015
      </year>
      <volume>
       373
      </volume>
      <fpage>
       1136
      </fpage>
      <lpage>
       1152
      </lpage>
      <pub-id pub-id-type="pmid">
       26376137
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMra1406184
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR9">
     <label>
      9.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Haubner
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
      </article-title>
      <source>
       Leukemia
      </source>
      <year>
       2019
      </year>
      <volume>
       33
      </volume>
      <fpage>
       64
      </fpage>
      <lpage>
       74
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BB3c%2FitFGqsA%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       29946192
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41375-018-0180-3
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR10">
     <label>
      10.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ehninger
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
      </article-title>
      <source>
       Blood Cancer J.
      </source>
      <year>
       2014
      </year>
      <volume>
       4
      </volume>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BC2cfis1yktA%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       24927407
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4080210
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/bcj.2014.39
      </pub-id>
      <elocation-id>
       e218
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR11">
     <label>
      11.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Dutour
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia
      </article-title>
      <source>
       Adv. Hematol.
      </source>
      <year>
       2012
      </year>
      <volume>
       2012
      </volume>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BC387nt1WhtA%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       22272203
      </pub-id>
      <pub-id pub-id-type="pmcid">
       3261457
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1155/2012/683065
      </pub-id>
      <elocation-id>
       683065
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR12">
     <label>
      12.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kim
        </surname>
        <given-names>
         MY
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia
      </article-title>
      <source>
       Cell
      </source>
      <year>
       2018
      </year>
      <volume>
       173
      </volume>
      <fpage>
       1439
      </fpage>
      <lpage>
       1453.e19
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1cXhtVKntrfP
      </pub-id>
      <pub-id pub-id-type="pmid">
       29856956
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6003425
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.cell.2018.05.013
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR13">
     <label>
      13.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Reindl
        </surname>
        <given-names>
         LM
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Immunotherapy with NK cells: recent developments in gene modification open up new avenues
      </article-title>
      <source>
       Oncoimmunology
      </source>
      <year>
       2020
      </year>
      <volume>
       9
      </volume>
      <pub-id pub-id-type="pmid">
       33457093
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7781759
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1080/2162402X.2020.1777651
      </pub-id>
      <elocation-id>
       1777651
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR14">
     <label>
      14.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Szczepanski
        </surname>
        <given-names>
         MJ
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors
      </article-title>
      <source>
       Cancer Immunol. Immunother.
      </source>
      <year>
       2010
      </year>
      <volume>
       59
      </volume>
      <fpage>
       73
      </fpage>
      <lpage>
       79
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD1MXht1OnsL%2FO
      </pub-id>
      <pub-id pub-id-type="pmid">
       19526239
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1007/s00262-009-0724-5
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR15">
     <label>
      15.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Rubnitz
        </surname>
        <given-names>
         JE
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia
      </article-title>
      <source>
       J. Clin. Oncol.
      </source>
      <year>
       2010
      </year>
      <volume>
       28
      </volume>
      <fpage>
       955
      </fpage>
      <lpage>
       959
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC3cXktF2ltrw%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       20085940
      </pub-id>
      <pub-id pub-id-type="pmcid">
       2834435
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1200/JCO.2009.24.4590
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR16">
     <label>
      16.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Romee
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
      </article-title>
      <source>
       Sci. Transl. Med.
      </source>
      <year>
       2016
      </year>
      <volume>
       8
      </volume>
      <fpage>
       357ra123
      </fpage>
      <pub-id pub-id-type="pmid">
       27655849
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5436500
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1126/scitranslmed.aaf2341
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR17">
     <label>
      17.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Miller
        </surname>
        <given-names>
         JS
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
      </article-title>
      <source>
       Blood
      </source>
      <year>
       2005
      </year>
      <volume>
       105
      </volume>
      <fpage>
       3051
      </fpage>
      <lpage>
       3057
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD2MXjtlSmtb0%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       15632206
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/blood-2004-07-2974
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR18">
     <label>
      18.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Paczulla
        </surname>
        <given-names>
         AM
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
      </article-title>
      <source>
       Nature
      </source>
      <year>
       2019
      </year>
      <volume>
       572
      </volume>
      <fpage>
       254
      </fpage>
      <lpage>
       259
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1MXhtl2qsLvF
      </pub-id>
      <pub-id pub-id-type="pmid">
       31316209
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6934414
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41586-019-1410-1
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR19">
     <label>
      19.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Albinger
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia
      </article-title>
      <source>
       Blood Cancer J.
      </source>
      <year>
       2022
      </year>
      <volume>
       12
      </volume>
      <pub-id pub-id-type="pmid">
       35418180
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9007937
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41408-022-00660-2
      </pub-id>
      <elocation-id>
       61
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR20">
     <label>
      20.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Albinger
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia
      </article-title>
      <source>
       Bone Marrow Transpl.
      </source>
      <year>
       2024
      </year>
      <volume>
       59
      </volume>
      <fpage>
       489
      </fpage>
      <lpage>
       495
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXhvFartb0%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41409-023-02180-4
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR21">
     <label>
      21.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Braud
        </surname>
        <given-names>
         VM
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
      </article-title>
      <source>
       Nature
      </source>
      <year>
       1998
      </year>
      <volume>
       391
      </volume>
      <fpage>
       795
      </fpage>
      <lpage>
       799
      </lpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       1998Natur.391..795B
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DyaK1cXhtlCjtbo%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       9486650
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/35869
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR22">
     <label>
      22.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Le Dréan
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases
      </article-title>
      <source>
       Eur. J. Immunol.
      </source>
      <year>
       1998
      </year>
      <volume>
       28
      </volume>
      <fpage>
       264
      </fpage>
      <lpage>
       276
      </lpage>
      <pub-id pub-id-type="pmid">
       9485206
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1002/(SICI)1521-4141(199801)28:01&lt;264::AID-IMMU264&gt;3.0.CO;2-O
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR23">
     <label>
      23.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         André
        </surname>
        <given-names>
         P
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells
      </article-title>
      <source>
       Cell
      </source>
      <year>
       2018
      </year>
      <volume>
       175
      </volume>
      <fpage>
       1731
      </fpage>
      <lpage>
       1743.e13
      </lpage>
      <pub-id pub-id-type="pmid">
       30503213
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6292840
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.cell.2018.10.014
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR24">
     <label>
      24.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Tognarelli
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Enhancing the activation and releasing the brakes: a double hit strategy to improve NK cell cytotoxicity against multiple myeloma
      </article-title>
      <source>
       Front Immunol.
      </source>
      <year>
       2018
      </year>
      <volume>
       9
      </volume>
      <fpage>
       2743
      </fpage>
      <pub-id pub-id-type="pmid">
       30542346
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6277768
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2018.02743
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR25">
     <label>
      25.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bexte
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma
      </article-title>
      <source>
       Oncoimmunology
      </source>
      <year>
       2022
      </year>
      <volume>
       11
      </volume>
      <pub-id pub-id-type="pmid">
       35694192
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9176243
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1080/2162402X.2022.2081415
      </pub-id>
      <elocation-id>
       2081415
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR26">
     <label>
      26.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bexte
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <name>
        <surname>
         Reindl
        </surname>
        <given-names>
         LM
        </given-names>
       </name>
       <name>
        <surname>
         Ullrich
        </surname>
        <given-names>
         E
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Nonviral technologies can pave the way for CAR-NK cell therapy
      </article-title>
      <source>
       J. Leukoc. Biol.
      </source>
      <year>
       2023
      </year>
      <volume>
       114
      </volume>
      <fpage>
       475
      </fpage>
      <lpage>
       486
      </lpage>
      <pub-id pub-id-type="pmid">
       37403203
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/jleuko/qiad074
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR27">
     <label>
      27.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Holling
        </surname>
        <given-names>
         TM
        </given-names>
       </name>
       <name>
        <surname>
         Schooten
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <name>
        <surname>
         van Den Elsen
        </surname>
        <given-names>
         PJ
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men
      </article-title>
      <source>
       Hum. Immunol.
      </source>
      <year>
       2004
      </year>
      <volume>
       65
      </volume>
      <fpage>
       282
      </fpage>
      <lpage>
       290
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD2cXjs1Gitrc%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       15120183
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.humimm.2004.01.005
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR28">
     <label>
      28.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Post
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       The transcription factor ZNF683/HOBIT regulates human NK-cell development
      </article-title>
      <source>
       Front. Immunol.
      </source>
      <year>
       2017
      </year>
      <volume>
       8
      </volume>
      <fpage>
       535
      </fpage>
      <pub-id pub-id-type="pmid">
       28555134
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5430038
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2017.00535
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR29">
     <label>
      29.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Metkar
        </surname>
        <given-names>
         SS
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Granzyme B activates procaspase-3 which signals a mitochondrial amplification loop for maximal apoptosis
      </article-title>
      <source>
       J. Cell Biol.
      </source>
      <year>
       2003
      </year>
      <volume>
       160
      </volume>
      <fpage>
       875
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD3sXitlSltrg%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       12629051
      </pub-id>
      <pub-id pub-id-type="pmcid">
       2173758
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1083/jcb.200210158
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR30">
     <label>
      30.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Jayavelu
        </surname>
        <given-names>
         AK
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       The proteogenomic subtypes of acute myeloid leukemia
      </article-title>
      <source>
       Cancer Cell
      </source>
      <year>
       2022
      </year>
      <volume>
       40
      </volume>
      <fpage>
       301
      </fpage>
      <lpage>
       317.e12
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XlvVekurs%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       35245447
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.ccell.2022.02.006
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR31">
     <label>
      31.
     </label>
     <mixed-citation publication-type="other">
      013062 - NSG-SGM3 Strain Details.
      <ext-link ext-link-type="uri" xlink:href="https://www.jax.org/strain/013062">
       https://www.jax.org/strain/013062#
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR32">
     <label>
      32.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wunderlich
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3
      </article-title>
      <source>
       Leukemia
      </source>
      <year>
       2010
      </year>
      <volume>
       24
      </volume>
      <fpage>
       1785
      </fpage>
      <lpage>
       1788
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BC3cfovVWmug%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       20686503
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5439963
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/leu.2010.158
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR33">
     <label>
      33.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Rasheed
        </surname>
        <given-names>
         HM
        </given-names>
       </name>
       <name>
        <surname>
         Donia
        </surname>
        <given-names>
         HM
        </given-names>
       </name>
       <name>
        <surname>
         Nadwan
        </surname>
        <given-names>
         EA
        </given-names>
       </name>
       <name>
        <surname>
         Mourad
        </surname>
        <given-names>
         ZI
        </given-names>
       </name>
       <name>
        <surname>
         Farahat
        </surname>
        <given-names>
         N
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Identifying leukemia-associated immunophenotypes in acute myeloid leukemia patients using multiparameter flow cytometry
      </article-title>
      <source>
       Oman Med. J.
      </source>
      <year>
       2021
      </year>
      <volume>
       36
      </volume>
      <fpage>
       e323
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38Xht1SltL%2FP
      </pub-id>
      <pub-id pub-id-type="pmid">
       35024173
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8722324
      </pub-id>
      <pub-id pub-id-type="doi">
       10.5001/omj.2021.108
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR34">
     <label>
      34.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Heuser
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
      </article-title>
      <source>
       Blood
      </source>
      <year>
       2021
      </year>
      <volume>
       138
      </volume>
      <fpage>
       2753
      </fpage>
      <lpage>
       2767
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XislGqsg%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       34724563
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8718623
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/blood.2021013626
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR35">
     <label>
      35.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ruggeri
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
      </article-title>
      <source>
       Science
      </source>
      <year>
       2002
      </year>
      <volume>
       295
      </volume>
      <fpage>
       2097
      </fpage>
      <lpage>
       2100
      </lpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2002Sci...295.2097R
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD38Xit1Ohurs%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       11896281
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1126/science.1068440
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR36">
     <label>
      36.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wendel
        </surname>
        <given-names>
         P
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Arming immune cells for battle: a brief journey through the advancements of T and NK cell immunotherapy
      </article-title>
      <source>
       Cancers (Basel)
      </source>
      <year>
       2021
      </year>
      <volume>
       13
      </volume>
      <fpage>
       1481
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXhslClsL3K
      </pub-id>
      <pub-id pub-id-type="pmid">
       33807011
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3390/cancers13061481
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR37">
     <label>
      37.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Cooley
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia
      </article-title>
      <source>
       Blood Adv.
      </source>
      <year>
       2019
      </year>
      <volume>
       3
      </volume>
      <fpage>
       1970
      </fpage>
      <lpage>
       1980
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhsVKgsLjM
      </pub-id>
      <pub-id pub-id-type="pmid">
       31266741
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6616260
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/bloodadvances.2018028332
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR38">
     <label>
      38.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Crinier
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia
      </article-title>
      <source>
       Cell Mol. Immunol.
      </source>
      <year>
       2021
      </year>
      <volume>
       18
      </volume>
      <fpage>
       1290
      </fpage>
      <lpage>
       1304
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXisVWnt7jM
      </pub-id>
      <pub-id pub-id-type="pmid">
       33239726
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41423-020-00574-8
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR39">
     <label>
      39.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Dufva
        </surname>
        <given-names>
         O
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers
      </article-title>
      <source>
       Immunity
      </source>
      <year>
       2023
      </year>
      <volume>
       56
      </volume>
      <fpage>
       2816
      </fpage>
      <lpage>
       2835.e13
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXis1WntLfF
      </pub-id>
      <pub-id pub-id-type="pmid">
       38091953
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.immuni.2023.11.008
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR40">
     <label>
      40.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Schneider
        </surname>
        <given-names>
         D
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       A unique human immunoglobulin heavy chain variable domain-only CD33 CAR for the treatment of acute myeloid leukemia
      </article-title>
      <source>
       Front. Oncol.
      </source>
      <year>
       2018
      </year>
      <volume>
       8
      </volume>
      <fpage>
       539
      </fpage>
      <pub-id pub-id-type="pmid">
       30524966
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6262782
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fonc.2018.00539
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR41">
     <label>
      41.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hejazi
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       CD33 delineates two functionally distinct NK cell populations divergent in cytokine production and antibody-mediated cellular cytotoxicity
      </article-title>
      <source>
       Front. Immunol.
      </source>
      <year>
       2021
      </year>
      <volume>
       12
      </volume>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhtFels7nE
      </pub-id>
      <pub-id pub-id-type="pmid">
       35058934
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2021.798087
      </pub-id>
      <elocation-id>
       798087
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR42">
     <label>
      42.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hunt
        </surname>
        <given-names>
         JMT
        </given-names>
       </name>
       <name>
        <surname>
         Samson
        </surname>
        <given-names>
         CA
        </given-names>
       </name>
       <name>
        <surname>
         Rand
        </surname>
        <given-names>
         Adu
        </given-names>
       </name>
       <name>
        <surname>
         Sheppard
        </surname>
        <given-names>
         HM
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells
      </article-title>
      <source>
       Hum. Genet.
      </source>
      <year>
       2023
      </year>
      <volume>
       142
      </volume>
      <fpage>
       705
      </fpage>
      <lpage>
       720
      </lpage>
      <pub-id pub-id-type="pmid">
       37093294
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10182114
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1007/s00439-023-02561-1
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR43">
     <label>
      43.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Rad
        </surname>
        <given-names>
         SMAH
        </given-names>
       </name>
       <name>
        <surname>
         Poudel
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <name>
        <surname>
         Tan
        </surname>
        <given-names>
         GMY
        </given-names>
       </name>
       <name>
        <surname>
         McLellan
        </surname>
        <given-names>
         AD
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Promoter choice: Who should drive the CAR in T cells?
      </article-title>
      <source>
       PLoS ONE
      </source>
      <year>
       2020
      </year>
      <volume>
       15
      </volume>
      <fpage>
       e0232915
      </fpage>
      <pub-id pub-id-type="doi">
       10.1371/journal.pone.0232915
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR44">
     <label>
      44.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Klermund
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       On- and off-target effects of paired CRISPR-Cas nickase in primary human cells
      </article-title>
      <source>
       Mol. Ther.
      </source>
      <year>
       2024
      </year>
      <volume>
       32
      </volume>
      <fpage>
       1298
      </fpage>
      <lpage>
       1310
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXmtFGms7o%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       38459694
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.ymthe.2024.03.006
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR45">
     <label>
      45.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Turchiano
        </surname>
        <given-names>
         G
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq
      </article-title>
      <source>
       Cell Stem Cell
      </source>
      <year>
       2021
      </year>
      <volume>
       28
      </volume>
      <fpage>
       1136
      </fpage>
      <lpage>
       1147.e5
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXltFOmurY%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       33626327
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.stem.2021.02.002
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR46">
     <label>
      46.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Nguyen
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       HLA-E upregulation on IFN-gamma-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT
      </article-title>
      <source>
       Bone Marrow Transpl.
      </source>
      <year>
       2009
      </year>
      <volume>
       43
      </volume>
      <fpage>
       693
      </fpage>
      <lpage>
       699
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD1MXlvVGrsL0%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/bmt.2008.380
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR47">
     <label>
      47.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Biederstädt
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <name>
        <surname>
         Rezvani
        </surname>
        <given-names>
         K
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy
      </article-title>
      <source>
       Blood
      </source>
      <year>
       2023
      </year>
      <volume>
       141
      </volume>
      <fpage>
       22
      </fpage>
      <lpage>
       38
      </lpage>
      <pub-id pub-id-type="pmid">
       35512203
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/blood.2021012411
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR48">
     <label>
      48.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Majzner
        </surname>
        <given-names>
         RG
        </given-names>
       </name>
       <name>
        <surname>
         Mackall
        </surname>
        <given-names>
         CL
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Clinical lessons learned from the first leg of the CAR T cell journey
      </article-title>
      <source>
       Nat. Med.
      </source>
      <year>
       2019
      </year>
      <volume>
       25
      </volume>
      <fpage>
       1341
      </fpage>
      <lpage>
       1355
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1MXhslelurbN
      </pub-id>
      <pub-id pub-id-type="pmid">
       31501612
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41591-019-0564-6
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR49">
     <label>
      49.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Daher
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells
      </article-title>
      <source>
       Blood
      </source>
      <year>
       2021
      </year>
      <volume>
       137
      </volume>
      <fpage>
       624
      </fpage>
      <lpage>
       636
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXjvVemsb8%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       32902645
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7869185
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/blood.2020007748
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR50">
     <label>
      50.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Jo
        </surname>
        <given-names>
         D-H
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles
      </article-title>
      <source>
       Mol. Ther. Methods Clin. Dev.
      </source>
      <year>
       2023
      </year>
      <volume>
       29
      </volume>
      <fpage>
       173
      </fpage>
      <lpage>
       184
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXmsFOgs7w%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       37063482
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10102412
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.omtm.2023.03.006
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR51">
     <label>
      51.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Lupo
        </surname>
        <given-names>
         KB
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy
      </article-title>
      <source>
       Nat. Commun.
      </source>
      <year>
       2024
      </year>
      <volume>
       15
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2024NatCo..15.1909L
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXlsVKmsrg%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       38429294
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10907695
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41467-024-46343-3
      </pub-id>
      <elocation-id>
       1909
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR52">
     <label>
      52.
     </label>
     <mixed-citation publication-type="other">
      Research, C. for B. E. and. FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies.
      <italic>
       FDA
      </italic>
      (2023).
     </mixed-citation>
    </ref>
    <ref id="CR53">
     <label>
      53.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bexte
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors
      </article-title>
      <source>
       Mol. Ther.
      </source>
      <year>
       2024
      </year>
      <volume>
       32
      </volume>
      <fpage>
       2357
      </fpage>
      <lpage>
       2372
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXht1ajtbvJ
      </pub-id>
      <pub-id pub-id-type="pmid">
       38751112
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.ymthe.2024.05.022
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR54">
     <label>
      54.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kath
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Integration of ζ-deficient CARs into the CD3ζ gene conveys potent cytotoxicity in T and NK cells
      </article-title>
      <source>
       Blood
      </source>
      <year>
       2024
      </year>
      <volume>
       143
      </volume>
      <fpage>
       2599
      </fpage>
      <lpage>
       2611
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXhtlOgtbnL
      </pub-id>
      <pub-id pub-id-type="pmid">
       38493479
      </pub-id>
      <pub-id pub-id-type="pmcid">
       11196866
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/blood.2023020973
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR55">
     <label>
      55.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Müller
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia
      </article-title>
      <source>
       Front Immunol.
      </source>
      <year>
       2019
      </year>
      <volume>
       10
      </volume>
      <fpage>
       3123
      </fpage>
      <pub-id pub-id-type="pmid">
       32117200
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2019.03123
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR56">
     <label>
      56.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Colamartino
        </surname>
        <given-names>
         ABL
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Efficient and robust NK-cell transduction with baboon envelope pseudotyped lentivector
      </article-title>
      <source>
       Front. Immunol.
      </source>
      <year>
       2019
      </year>
      <volume>
       10
      </volume>
      <fpage>
       2873
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhsVCgtrbO
      </pub-id>
      <pub-id pub-id-type="pmid">
       31921138
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6927467
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2019.02873
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR57">
     <label>
      57.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bari
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       A distinct subset of highly proliferative and lentiviral vector (LV)-transducible NK cells define a readily engineered subset for adoptive cellular therapy
      </article-title>
      <source>
       Front. Immunol.
      </source>
      <year>
       2019
      </year>
      <volume>
       10
      </volume>
      <fpage>
       2001
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXks1Squ70%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       31507603
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6713925
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2019.02001
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR58">
     <label>
      58.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Alzubi
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Automated generation of gene-edited CAR T cells at clinical scale
      </article-title>
      <source>
       Mol. Ther. Methods Clin. Dev.
      </source>
      <year>
       2021
      </year>
      <volume>
       20
      </volume>
      <fpage>
       379
      </fpage>
      <lpage>
       388
      </lpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2021tktf.book.....A
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXjtVSqt7o%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       33575430
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.omtm.2020.12.008
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR59">
     <label>
      59.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Livak
        </surname>
        <given-names>
         KJ
        </given-names>
       </name>
       <name>
        <surname>
         Schmittgen
        </surname>
        <given-names>
         TD
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method
      </article-title>
      <source>
       Methods
      </source>
      <year>
       2001
      </year>
      <volume>
       25
      </volume>
      <fpage>
       402
      </fpage>
      <lpage>
       408
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD38XhtFelt7s%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       11846609
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1006/meth.2001.1262
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR60">
     <label>
      60.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Riedel
        </surname>
        <given-names>
         G
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       An extended ΔCT-method facilitating normalisation with multiple reference genes suited for quantitative RT-PCR analyses of human hepatocyte-like cells
      </article-title>
      <source>
       PLoS ONE
      </source>
      <year>
       2014
      </year>
      <volume>
       9
      </volume>
      <fpage>
       e93031
      </fpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2014PLoSO...993031R
      </pub-id>
      <pub-id pub-id-type="pmid">
       24658132
      </pub-id>
      <pub-id pub-id-type="pmcid">
       3962476
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1371/journal.pone.0093031
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR61">
     <label>
      61.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         McCarthy
        </surname>
        <given-names>
         DJ
        </given-names>
       </name>
       <name>
        <surname>
         Campbell
        </surname>
        <given-names>
         KR
        </given-names>
       </name>
       <name>
        <surname>
         Lun
        </surname>
        <given-names>
         ATL
        </given-names>
       </name>
       <name>
        <surname>
         Wills
        </surname>
        <given-names>
         QF
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R
      </article-title>
      <source>
       Bioinformatics
      </source>
      <year>
       2017
      </year>
      <volume>
       33
      </volume>
      <fpage>
       1179
      </fpage>
      <lpage>
       1186
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1cXhvFagtL%2FP
      </pub-id>
      <pub-id pub-id-type="pmid">
       28088763
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5408845
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/bioinformatics/btw777
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR62">
     <label>
      62.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ilicic
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Classification of low quality cells from single-cell RNA-seq data
      </article-title>
      <source>
       Genome Biol.
      </source>
      <year>
       2016
      </year>
      <volume>
       17
      </volume>
      <pub-id pub-id-type="pmid">
       26887813
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4758103
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1186/s13059-016-0888-1
      </pub-id>
      <elocation-id>
       29
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR63">
     <label>
      63.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         AITCHISON
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         HO
        </surname>
        <given-names>
         CH
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       The multivariate Poisson-log normal distribution
      </article-title>
      <source>
       Biometrika
      </source>
      <year>
       1989
      </year>
      <volume>
       76
      </volume>
      <fpage>
       643
      </fpage>
      <lpage>
       653
      </lpage>
      <pub-id assigning-authority="American Mathematical Society" pub-id-type="other">
       1041409
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/biomet/76.4.643
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR64">
     <label>
      64.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Robinson
        </surname>
        <given-names>
         MD
        </given-names>
       </name>
       <name>
        <surname>
         McCarthy
        </surname>
        <given-names>
         DJ
        </given-names>
       </name>
       <name>
        <surname>
         Smyth
        </surname>
        <given-names>
         GK
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
      </article-title>
      <source>
       Bioinformatics
      </source>
      <year>
       2010
      </year>
      <volume>
       26
      </volume>
      <fpage>
       139
      </fpage>
      <lpage>
       140
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD1MXhs1WlurvO
      </pub-id>
      <pub-id pub-id-type="pmid">
       19910308
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/bioinformatics/btp616
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR65">
     <label>
      65.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ritchie
        </surname>
        <given-names>
         ME
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       limma powers differential expression analyses for RNA-sequencing and microarray studies
      </article-title>
      <source>
       Nucleic Acids Res.
      </source>
      <year>
       2015
      </year>
      <volume>
       43
      </volume>
      <fpage>
       e47
      </fpage>
      <pub-id pub-id-type="pmid">
       25605792
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4402510
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/nar/gkv007
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR66">
     <label>
      66.
     </label>
     <mixed-citation publication-type="other">
      Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments.
      <italic>
       Stat. Appl. Genet. Mol. Biol.
      </italic>
      <bold>
       3
      </bold>
      , 3 (2004).
     </mixed-citation>
    </ref>
    <ref id="CR67">
     <label>
      67.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Phipson
        </surname>
        <given-names>
         B
        </given-names>
       </name>
       <name>
        <surname>
         Lee
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <name>
        <surname>
         Majewski
        </surname>
        <given-names>
         IJ
        </given-names>
       </name>
       <name>
        <surname>
         Alexander
        </surname>
        <given-names>
         WS
        </given-names>
       </name>
       <name>
        <surname>
         Smyth
        </surname>
        <given-names>
         GK
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Robust hyperparameter estimation protects against hypervariable genes and improves power to detect differential expression
      </article-title>
      <source>
       Ann. Appl Stat.
      </source>
      <year>
       2016
      </year>
      <volume>
       10
      </volume>
      <fpage>
       946
      </fpage>
      <lpage>
       963
      </lpage>
      <pub-id assigning-authority="American Mathematical Society" pub-id-type="other">
       3528367
      </pub-id>
      <pub-id pub-id-type="pmid">
       28367255
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5373812
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1214/16-AOAS920
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR68">
     <label>
      68.
     </label>
     <mixed-citation publication-type="other">
      Wickham, H.
      <italic>
       Ggplot2
      </italic>
      (Springer International Publishing, 2016).
      <ext-link ext-link-type="doi" xlink:href="10.1007/978-3-319-24277-4">
       https://doi.org/10.1007/978-3-319-24277-4
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR69">
     <label>
      69.
     </label>
     <mixed-citation publication-type="other">
      The igraph software package for complex network research|BibSonomy.
      <ext-link ext-link-type="uri" xlink:href="https://www.bibsonomy.org/bibtex/bb49a4a77b42229a427fec316e9fe515">
       https://www.bibsonomy.org/bibtex/bb49a4a77b42229a427fec316e9fe515
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR70">
     <label>
      70.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Blondel
        </surname>
        <given-names>
         VD
        </given-names>
       </name>
       <name>
        <surname>
         Guillaume
        </surname>
        <given-names>
         J-L
        </given-names>
       </name>
       <name>
        <surname>
         Lambiotte
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <name>
        <surname>
         Lefebvre
        </surname>
        <given-names>
         E
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Fast unfolding of communities in large networks
      </article-title>
      <source>
       J. Stat. Mech.
      </source>
      <year>
       2008
      </year>
      <volume>
       2008
      </volume>
      <fpage>
       P10008
      </fpage>
      <pub-id pub-id-type="doi">
       10.1088/1742-5468/2008/10/P10008
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR71">
     <label>
      71.
     </label>
     <mixed-citation publication-type="other">
      Raivo Kolde. pheatmap: Pretty Heatmaps. 1.0.12
      <ext-link ext-link-type="doi" xlink:href="10.32614/CRAN.package.pheatmap">
       https://doi.org/10.32614/CRAN.package.pheatmap
      </ext-link>
      (2010).
     </mixed-citation>
    </ref>
    <ref id="CR72">
     <label>
      72.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Lun
        </surname>
        <given-names>
         ATL
        </given-names>
       </name>
       <name>
        <surname>
         McCarthy
        </surname>
        <given-names>
         DJ
        </given-names>
       </name>
       <name>
        <surname>
         Marioni
        </surname>
        <given-names>
         JC
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor
      </article-title>
      <source>
       F1000Res
      </source>
      <year>
       2016
      </year>
      <volume>
       5
      </volume>
      <fpage>
       2122
      </fpage>
      <pub-id pub-id-type="pmid">
       27909575
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5112579
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR73">
     <label>
      73.
     </label>
     <mixed-citation publication-type="other">
      van der Maaten, L. &amp; Hinton, G. Visualizing Data using t-SNE.
      <italic>
       J. Mach. Learn. Res.
      </italic>
      <bold>
       9
      </bold>
      , 2579–2605 (2008).
     </mixed-citation>
    </ref>
   </ref-list>
  </ref-list>
  <app-group>
   <app id="App1" specific-use="web-only">
    <sec id="Sec41">
     <title>
      Sehemu ya kusaidia
     </title>
     <p id="Par61">
      <supplementary-material content-type="local-data" id="MOESM1" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52388_MOESM1_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Supplementary Information
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM2" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52388_MOESM2_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Peer Review File
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM3" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52388_MOESM3_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Description of Additional Supplementary Files
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM4" xlink:title="Supplementary information">
       <media mime-subtype="quicktime" mimetype="video" xlink:href="MediaObjects/41467_2024_52388_MOESM4_ESM.mov">
        <caption xml:lang="en">
         <p>
          Supplementary Movie 1
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM5" xlink:title="Supplementary information">
       <media mime-subtype="quicktime" mimetype="video" xlink:href="MediaObjects/41467_2024_52388_MOESM5_ESM.mov">
        <caption xml:lang="en">
         <p>
          Supplementary Movie 2
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM6" xlink:title="Supplementary information">
       <media mime-subtype="quicktime" mimetype="video" xlink:href="MediaObjects/41467_2024_52388_MOESM6_ESM.mov">
        <caption xml:lang="en">
         <p>
          Supplementary Movie 3
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM7" xlink:title="Supplementary information">
       <media mime-subtype="quicktime" mimetype="video" xlink:href="MediaObjects/41467_2024_52388_MOESM7_ESM.mov">
        <caption xml:lang="en">
         <p>
          Supplementary Movie 4
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM8" xlink:title="Supplementary information">
       <media mime-subtype="quicktime" mimetype="video" xlink:href="MediaObjects/41467_2024_52388_MOESM8_ESM.mov">
        <caption xml:lang="en">
         <p>
          Supplementary Movie 5
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM9" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52388_MOESM9_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Reporting Summary
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
    <sec id="Sec42">
     <title>
      Sehemu ya kusaidia
     </title>
     <p id="Par62">
      <supplementary-material content-type="local-data" id="MOESM10" xlink:title="Source data">
       <media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="MediaObjects/41467_2024_52388_MOESM10_ESM.xlsx">
        <caption xml:lang="en">
         <p>
          Source data
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
   </app>
  </app-group>
  <notes notes-type="ESMHint">
   <title/>
   <p>
    The online version contains supplementary material available at
    <ext-link ext-link-type="doi" xlink:href="10.1038/s41467-024-52388-1">
     https://doi.org/10.1038/s41467-024-52388-1
    </ext-link>
    .
   </p>
  </notes>
  <notes notes-type="Misc">
   <p>
    <bold>
     Publisher’s note
    </bold>
    Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
   </p>
  </notes>
 </back>
</article>
